Document:

EXHIBIT 10.3

 

THIS
INTELLECTUAL PROPERTY SECURITY AGREEMENT IS SUBJECT TO THE TERMS OF THAT
CERTAIN INTERCREDITOR AGREEMENT (as defined below).

 

INTELLECTUAL
PROPERTY SECURITY AGREEMENT

 

This
Intellectual Property Security Agreement (“IP Security Agreement”) is
made as of August 13, 2010, by and between ARYx
Therapeutics, Inc., a Delaware corporation (“Debtor”),
and the lenders listed on the signature pages hereto (each, a “Lender”
and, collectively, the “Lenders”).

 

RECITALS

 

A.                                   Debtor is
indebted to Lenders for loans advanced and other financial accommodations
provided pursuant to that certain Secured Note and Warrant Purchase Agreement
dated August 13, 2010 (“Purchase Agreement”).

 

B.                                     Debtor has
granted a security interest in certain intangible property to Lenders for
purposes of securing the obligations of Debtor to Lenders, pursuant to that
certain Security Agreement dated August 13, 2010 (“Security Agreement”).

 

C.                                     In
consideration of value and other financial accommodations provided by Lenders
and on account of amounts due Lenders, Debtor has agreed to grant Lenders the
security interests in Debtor’s intellectual property on the terms set forth
herein.

 

NOW,
THEREFORE, the parties hereto agree as follows:

 

1.                                      Definitions.  The following capitalized terms shall mean
the following in this Agreement.

 

1.1                               “Intercreditor Agreement” has the
meaning ascribed to the term in the Purchase Agreement.

 

1.2                               “IP Collateral” means all of the
following now or hereafter existing, created or acquired or held by Debtor:

 

(a)                                  Any and all copyright rights, copyright applications, copyright
registrations and like protections in each work of authorship and derivative
work thereof, whether published or unpublished and whether or not the same also
constitutes a trade secret, including, without limitation, those set forth on Exhibit A
attached hereto and incorporated herein by this reference (collectively, the “Copyrights”);

 

(b)                                 Any and all trade secrets, any and all intellectual property rights in
computer software and computer software products, and any other proprietary
rights to any process, method or technology of any kind or nature;

 

(c)                                  Any and all design rights which may be available to Debtor;

 

(d)                                 All patents, patent applications and like protections including, without
limitation, those set forth on Exhibit B attached hereto and
incorporated herein by this reference together with all improvements,
extensions, reissues, substitutes, continuations, continuations-in-part,
divisionals, patents of addition, re-examinations and renewals thereof, and
patents issuing therefrom, and any other proprietary rights related to any of
the foregoing (including, without limitation, remedies against infringements
thereof and rights of protection of an interest therein under the laws of all jurisdictions)
and any and all foreign counterparts of any of the foregoing (collectively, the
“Patents”);

 

 

(e)                                  All trademark and service mark rights, whether registered or not,
applications to register and registrations of the same and like protections,
and the entire goodwill of the business of Debtor connected with and symbolized
by such trademarks, including, without limitation, those set forth on Exhibit C
attached hereto and incorporated herein by this reference together with all
extensions, reissues, substitutes, continuations, and renewals thereof, and any
other proprietary rights related to any of the foregoing (including, without
limitation, remedies against infringements thereof and rights of protection of
an interest therein under the laws of all jurisdictions) and any and all
foreign counterparts of any of the foregoing;
(collectively, the “Trademarks”);

 

(f)                                    Any and all claims for damages by way of past, present and future
infringement of any of the rights included above, with the right, but not the
obligation, to sue for and collect such damages for said use or infringement of
the intellectual property rights identified above;

 

(g)                                 All licenses or other rights to use any of the Copyrights, Patents or
Trademarks, and all license fees and royalties arising from such use to the
extent permitted by such license or rights;

 

(h)                                 All amendments, renewals and extensions of any of the Copyrights, Patents
or Trademarks; and

 

(i)                                     Any and all proceeds, products, replacements, additions, accessions and
substitutions of or with respect to any of the foregoing, including, without
limitation, all payments under insurance or any indemnity or warranty payable
in respect of any of the foregoing.

 

1.3                               “LCP” means Lighthouse Capital Partners
V, L.P.

 

1.4                               “Loan Documents” has the meaning
ascribed to the term in the Purchase Agreement.

 

1.5                               “Secured Obligations” has the meaning
ascribed to the term in the Security Agreement.

 

2.                                      Grant of Junior Security Interest.  As collateral security for the prompt and
complete payment and performance of all of Debtor’s present or future
indebtedness, obligations and liabilities to Lenders, including without
limitation, the Secured Obligations, Debtor hereby transfers, conveys and
grants a security interest in and mortgages to Lenders, as security, in and to
Debtor’s entire right, title and interest in, to and under the IP Collateral.

 

3.                                      Authorization and Request.  Debtor authorizes and requests that the
Registrar of Copyrights and the Commissioner of Patents and Trademarks record this
IP Security Agreement.

 

4.                                      Covenants and Warranties.  Debtor represents, warrants, covenants and
agrees as follows:

 

4.1                               Debtor is now the sole owner of the IP
Collateral, except for the non-exclusive licenses granted by Debtor to its
customers in the ordinary and normal course of business as now conducted;

 

4.2                               Performance of this IP Security Agreement does
not conflict with or result in a breach of any agreement to which Debtor is a
party or by which Debtor is bound, except to the extent that certain intellectual
property agreements prohibit the assignment of the rights thereunder to a third
party without the licensor’s or other party’s consent and this IP Security
Agreement constitutes an assignment;

 

 

4.3                               During the term of this IP Security Agreement,
Debtor shall not without Lenders’ prior written authorization sell, transfer,
assign or otherwise encumber any interest in the IP Collateral, except
(i) for non-exclusive licenses granted by Debtor in the ordinary and
normal course of its business as now conducted or as set forth in this IP
Security Agreement; (ii) security interest in favor of LCP; and
(iii) subject to Debtor’s execution of appropriate documents, in a form
acceptable to Lenders, to perfect or continue the perfection of Lenders’
interest in the IP Collateral, or transfers to affiliates of Debtor;

 

4.4                               To its knowledge, each of the Patents is valid
and enforceable, and no part of the IP Collateral has been judged invalid or
unenforceable, in whole or in part, and no claim has been made that any part of
the IP Collateral violates the rights of any third party;

 

4.5                               Debtor shall advise Lenders of any material
changes in the composition of the IP Collateral by identifying such material
changes in the Quarterly Report (as hereinafter defined), including but not
limited to any subsequent ownership right of Debtor in or to any Copyright,
Patent or Trademark not specified in this IP Security Agreement;

 

4.6                               Debtor shall (i) protect, defend and
maintain the validity and enforceability of the Copyrights, Patents and
Trademarks, (ii) use its best efforts to detect infringements of the
Copyrights, Patents and Trademarks and promptly advise Lenders in writing of
material infringements detected and (iii) not allow any Copyrights,
Patents or Trademarks to be abandoned, forfeited or dedicated to the public
without the written consent of Lenders, which shall not be unreasonably
withheld, unless Debtor determines that reasonable business practices suggest
that abandonment is appropriate;

 

4.7                               Debtor shall promptly register the most recent
version of Debtor’s material Copyrights, Patents and Trademarks if not so
already registered, as Lenders may reasonably request from time to time based
on its review of the Quarterly Report (as hereinafter defined) and shall, from
time to time, execute and file such other instruments, and take such further
actions as Lenders may reasonably request from time to time to perfect or
continue the perfection of Lenders’ interest in the IP Collateral;

 

4.8                               This IP Security Agreement creates, and in the
case of after acquired IP Collateral, this IP Security Agreement will create at
the time Debtor first has rights in such after acquired IP Collateral, in favor
of Lenders valid and perfected security interests in the IP Collateral in the
United States securing the payment and performance of all present or future
indebtedness, obligations and liabilities of Debtor to Lenders, including,
without limitation, such indebtedness, obligations and liabilities under the
Purchase Agreement and the other Loan Documents, upon the filing of financing
statements in the appropriate filing office;

 

4.9                               To its knowledge, except for, and upon, the
filings with, as applicable, (1) the United States Patent and Trademark
office with respect to the Patents and Trademarks, (2) the Register of
Copyrights with respect to the Copyrights and (3) the UCC Division of the
Secretary of State of Delaware, necessary to perfect the security interests
created hereunder, and except as has been already made or obtained, no authorization,
approval or other action by, and no notice to or filing with, any United States
governmental authority or United States regulatory body is required either
(a) for the grant by Debtor of the security interests granted hereby or
for the execution, delivery or performance of this IP Security Agreement by
Debtor in the United States or (b) for the perfection in the United States
or the exercise by Lenders of its rights and remedies hereunder;

 

4.10                        All information heretofore, herein or
hereafter supplied to Lenders by or on behalf of Debtor with respect to the IP
Collateral is accurate and complete in all material respects;

 

4.11                        Debtor shall not enter into any agreement that
would materially impair or conflict with Debtor’s obligations hereunder without
Lenders’ prior written authorization, which authorization 

 

 

shall
not be unreasonably withheld.  Debtor
shall not permit the inclusion in any material contract to which it becomes a
party of any provisions that could or might in any way prevent the creation of
a security interest in Debtor’s rights and interests in any property included
within the definition of the IP Collateral acquired under such contracts;

 

4.12                        Upon any executive officer of Debtor obtaining
actual knowledge thereof, Debtor will promptly notify Lenders in writing of any
event that materially adversely affects the value of any IP Collateral, the
ability of Debtor to dispose of any IP Collateral or the rights and remedies of
Lenders in relation thereto, including the levy of any legal process against
any of the IP Collateral; and

 

4.13                        Within ten (10) days of the date hereof,
Debtor shall, with respect to all U.S. Patents (and Patent applications) listed
on Exhibit B cause to be filed and recorded recordation notices at
the United States Patent and Trademark Office of the assignments evidencing the
ownership of such Patents and patent applications in the sole name of the
Debtor.

 

5.                                      Lenders’ Rights.  Subject to the terms of the Intercreditor
Agreement, Lenders shall have the right, but not the obligation, to take, at
Debtor’s sole expense, any actions that Debtor is required under this IP
Security Agreement to take but which Debtor fails to take, after fifteen (15)
days’ notice to Debtor.  Debtor shall
reimburse and indemnify Lenders for all reasonable costs and reasonable
expenses incurred in the reasonable exercise of its rights under this Section 5.

 

6.                                      Inspection Rights.  Debtor hereby grants to Lenders and their
employees, representatives and agent’s the right to visit once per calendar
year (unless an Event of Default has occurred and is continuing), during
reasonable hours upon prior reasonable written notice to Debtor, any of Debtor’s
plants and facilities that manufacture, install or store products (or that have
done so during the prior six-month period) that are sold utilizing any of the
IP Collateral, and to inspect the products and quality control records relating
thereto upon reasonable written notice to Debtor and as often as may be
reasonably requested.

 

7.                                      Further Assurances; Attorney In Fact.
Subject to the terms of the Intercreditor Agreement:

 

7.1                               On a quarterly basis, Debtor agrees to deliver
to Lenders a report, in form acceptable to Lenders and certified by an officer
of Debtor, which lists all Copyrights, Patents and Trademarks that are material
to the operation of Debtor’s business on an on-going basis, and in which
Lenders do not already have perfected security interests (the “Quarterly
Report”); provided, however, Debtor may provide a general
description of the Copyrights by type.

 

7.2                               On a continuing basis, Debtor will make,
execute, acknowledge and deliver, and file and record in the proper filing and
recording places in the United States, all such instruments, including
appropriate financing and continuation statements and collateral agreements and
filings with the United States Patent and Trademark Office and the Register of
Copyrights, and take all such action as may reasonably be necessary or
advisable, or as reasonably requested by Lenders, to perfect Lenders’ security
interest in all Copyrights, Patents and Trademarks, which Lenders reasonably
identify pursuant to Section 4.7 above as material to the operation
of Debtor’s business on an on-going basis or the value of the IP Collateral,
and otherwise to carry out the intent and purposes of this IP Security
Agreement, or for assuring and confirming to Lenders the grant or perfection of
a security interests in all IP Collateral.

 

7.3                               Debtor hereby irrevocably appoints Lenders as
Debtor’s attorney-in-fact, with full authority in the place and stead of Debtor
and in the name of Debtor, from time to time in Lenders’ discretion, to take
any of the following actions and to execute any of the following instruments
(i) modify, in its reasonable discretion, this IP Security Agreement
without first obtaining Debtor’s approval of or 

 

 

signature
to such modification by amending Exhibit A, Exhibit B
or Exhibit C hereof, as appropriate, to include reference to any
material right, title or interest in any Copyrights, Patents or Trademarks
acquired by Debtor after the execution hereof or to delete any reference to any
right, title or interest in any Copyrights, Patents or Trademarks in which
Debtor no longer has or claims any right, title or interest, (ii) file, in
its reasonable discretion, one or more financing or continuation statements and
amendments thereto, relative to any of the IP Collateral without the signature
of Debtor where permitted by law and (iii) after the occurrence and during
the continuance of an Event of Default, to transfer the IP Collateral into the
name of any or all Lenders or a third party to the extent permitted under the
California Uniform Commercial Code.

 

8.                                      Events of Default.  The occurrence of any of the following shall
constitute an “Event of Default” under this IP Security Agreement:

 

8.1                               An Event of Default occurs under the Purchase
Agreement or any of the other Loan Documents;

 

8.2                               Debtor breaches any warranty or agreement in
any material respect made by Debtor in this IP Security Agreement and, as to
any breach that is capable of cure, Debtor fails to cure such breach within
thirty (30) days of the occurrence of such breach;

 

8.3                               Debtor shall fail to comply with the covenant
set forth in Section 4 hereof; and

 

8.4                               Any default under that certain Oxford Loan and
Security Agreement No. 4521, dated as of March 28, 2005, by and
between the Grantor and LCP, as amended, modified or supplement from time to
time.

 

9.                                      Remedies.  Upon the occurrence and during the
continuance of an Event of Default, Lenders shall have the right to exercise
all the remedies of a secured party under the California Uniform Commercial
Code, including, without limitation, the right to require Debtor to assemble
the IP Collateral and any tangible property in which any Lender has security
interests and to make it available to Lenders at a place designated by
Lenders.  Lenders shall have a
nonexclusive, royalty free license to use the Copyrights, Patents and
Trademarks to the extent reasonably necessary to permit Lenders to exercise its
rights and remedies upon the occurrence and during the continuance of an Event
of Default.  Debtor will pay any expenses
(including reasonable attorneys’ fees) incurred by Lenders in connection with
the exercise of any of Lenders’ rights hereunder, including, without
limitation, any expense incurred in disposing of the IP Collateral.  All of Lenders’ rights and remedies with
respect to the IP Collateral shall be cumulative.  This Section 9 is subject to the terms
of the Intercreditor Agreement.

 

10.                               Indemnity.  Debtor agrees to defend, indemnify and hold
harmless Lenders and their officers, employees, and agents against:
(a) all obligations, demands, claims, and liabilities claimed or asserted
by any other party in connection with the transactions contemplated by this IP
Security Agreement and (b) all losses or expenses in any way suffered,
incurred, or paid by any of them as a result of or in any way arising out of,
following or consequential to transactions between any or all Lenders and
Debtor, whether under this IP Security Agreement or otherwise (including,
without limitation, reasonable attorneys’ fees and reasonable expenses), except
for claims and losses described in clauses (a) and (b), arising from or
out of the gross negligence or willful misconduct of any Lender.

 

11.                               Termination.  At such time as Debtor shall completely
satisfy all of the obligations secured hereunder or otherwise pursuant to the
terms of the Loan Documents, Lenders shall execute and deliver to Debtor all
deeds, assignments and other instruments as may be necessary or proper to
terminate the security interests granted hereunder, subject to any disposition
thereof which may have been made by Lenders pursuant hereto.

 

 

12.                               No Failure or Delay.  No failure or delay on the part of Lenders,
in the exercise of any power, right or privilege hereunder shall operate as a
waiver thereof, nor shall any single or partial exercise thereof.

 

13.                               Attorneys’ Fees. Debtor shall pay
Lenders on demand all reasonable attorneys and/or legal fees and all other
costs and expenses incurred by Lenders in enforcing Lenders’ rights under this
IP Security Agreement, including without limitation all costs of preserving or
disposing of the IP Collateral.

 

14.                               Amendments.  This IP Security Agreement may be amended
only by a written instrument signed by Lenders.

 

15.                               Counterparts.  This IP Security Agreement may be executed in
any number of counterparts, each of which when so delivered shall be deemed an
original, but all such counterparts shall constitute but one and the same
instrument.  This IP Security Agreement
shall become effective upon the execution of a counterpart hereof or thereof by
each of the parties hereto and telephonic notification that such executed counterparts
has been received by Debtor and each Lender.

 

16.                               Governing Law; Jurisdiction; Jury Waiver.  This IP Security Agreement shall
be governed by, and construed in accordance with, the internal laws of the
State of California, without regard to principles of conflicts of law.  Debtor and Lenders consent to the exclusive
jurisdiction of any state or federal court located in San Francisco County,
California.  DEBTOR AND LENDERS EACH WAIVE THEIR RESPECTIVE RIGHTS TO A JURY TRIAL OF
ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS IP SECURITY
AGREEMENT AND ANY OTHER LOAN DOCUMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED
HEREIN, INCLUDING CONTRACT CLAIMS, TORT CLAIMS, BREACH OF DUTY CLAIMS, AND
ALL OTHER COMMON LAW OR STATUTORY CLAIMS.

 

17.                               Conflict.  In the event of a conflict between any term
and/or provision contained in this IP Security Agreement with any term and/or
provision contained in any of the Loan Documents, the term and/or provision of
the Purchase Agreement shall govern.

 

REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK

 

 

IN WITNESS WHEREOF, the
parties hereto have executed this Security Agreement on the day and year first
above written.

 

“Debtor”

 

ARYx THERAEUTICS, INC.

 

 

	
  By:

  	
  /s/
  Paul Goddard

  	
   

  
	
   

  	
   

  
	
  Name:

  	
  Paul
  Goddard, Ph.D.

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Chairman
  and Chief Executive Officer

  	
   

  

 

SIGNATURE PAGE TO ARYx
THERAPEUTICS, INC.

BRIDGE INTELLECTUAL
PROPERTY SECURITY AGREEMENT

 

 

	
  “Lenders”

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  AYER CAPITAL PARTNERS MASTER
  FUND, L.P.

  	
   

  
	
   

  	
   

  
	
  By:
  Ayer Capital Partners, LLC, its general partner

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/
  Jay Venkatesan

  	
   

  
	
   

  	
   

  
	
  Print
  Name:

  	
  Jay
  Venkatesan

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Managing
  Member

  	
   

  
	
   

  	
   

  
	
  Address:

  	
  Ayer Capital Management,
  L.P.

  	
   

  
	
   

  	
  Attn: Jay Venkatesan

  	
   

  
	
   

  	
  230 California Street,
  Suite 600

  	
   

  
	
   

  	
  San
  Francisco, CA 94111

  	
   

  
	
   

  	
  fax: (415) 651-9005

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  AYER CAPITAL PARTNERS KESTREL
  FUND, L.P.

  	
   

  
	
   

  	
   

  
	
  By:
  Ayer Kestrel Partners, LLC, its general partner

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/
  Jay Venkatesan

  	
   

  
	
   

  	
   

  
	
  Print
  Name:

  	
  Jay
  Venkatesan

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Managing
  Member

  	
   

  
	
   

  	
   

  
	
  Address:

  	
  Ayer Capital Management,
  L.P.

  	
   

  
	
   

  	
  Attn: Jay Venkatesan

  	
   

  
	
   

  	
  230 California Street,
  Suite 600

  	
   

  
	
   

  	
  San
  Francisco, CA 94111

  	
   

  
	
   

  	
  fax:
  (415) 651-9005

  	
   

  
						

 

SIGNATURE PAGE TO ARYx
THERAPEUTICS, INC.

BRIDGE INTELLECTUAL
PROPERTY SECURITY AGREEMENT

 

 

	
  “Lenders”

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  MPM
  BioVentures III GP, L.P., its General Partner

  	
   

  
	
   

  	
   

  
	
  By: MPM BioVentures III
  LLC, its General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/
  Nicholas Simon III

  	
   

  
	
   

  	
   

  
	
  Print
  Name:

  	
  Nicholas
  Simon III

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Series A
  Member

  	
   

  
	
   

  	
   

  
	
  Address:

  	
  200
  Clarendon Street, 54th Floor

  	
   

  
	
   

  	
  Boston,
  MA 02116

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III-QP, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  MPM
  BioVentures III GP, L.P., its General Partner

  	
   

  
	
   

  	
   

  
	
  By: MPM BioVentures III
  LLC, its General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/
  Nicholas Simon III

  	
   

  
	
   

  	
   

  
	
  Print
  Name:

  	
  Nicholas
  Simon III

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Series A
  Member

  	
   

  
	
   

  	
   

  
	
  Address:

  	
  200
  Clarendon Street, 54th Floor

  	
   

  
	
   

  	
  Boston,
  MA 02116

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III
  GMBH & CO. BETEILIGUNGS KG

  
	
   

  	
   

  
	
  By:  MPM BioVentures III GP,
  L.P., in its capacity as Managing Limited Partner

  
	
   

  	
   

  
	
  By: MPM BioVentures III
  LLC, its General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/
  Nicholas Simon III

  	
   

  
	
   

  	
   

  
	
  Print
  Name:

  	
  Nicholas
  Simon III

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Series A
  Member

  	
   

  
	
   

  	
   

  
	
  Address:

  	
  200
  Clarendon Street, 54th Floor

  	
   

  
	
   

  	
  Boston,
  MA 02116

  	
   

  
									

 

SIGNATURE PAGE TO ARYx
THERAPEUTICS, INC.

BRIDGE INTELLECTUAL
PROPERTY SECURITY AGREEMENT

 

 

	
  “Lenders”

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III PARALLEL FUND, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  MPM
  BioVentures III GP, L.P., its General Partner

  	
   

  
	
   

  	
   

  
	
  By: MPM BioVentures III
  LLC, its General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/
  Nicholas Simon III

  	
   

  
	
   

  	
   

  
	
  Print
  Name:

  	
  Nicholas
  Simon III

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Series A
  Member

  	
   

  
	
   

  	
   

  
	
  Address:

  	
  200
  Clarendon Street, 54th Floor

  	
   

  
	
   

  	
  Boston,
  MA 02116

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  MPM BIOVENTURES III-QP, L.P.

  	
   

  
	
   

  	
   

  
	
  By:  MPM
  BioVentures III GP, L.P., its General Partner

  	
   

  
	
   

  	
   

  
	
  By: MPM BioVentures III
  LLC, its General Partner

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
  By:

  	
  /s/
  Nicholas Simon III

  	
   

  
	
   

  	
   

  
	
  Print
  Name:

  	
  Nicholas
  Simon III

  	
   

  
	
   

  	
   

  
	
  Title:

  	
  Series A
  Member

  	
   

  
	
   

  	
   

  
	
  Address:

  	
  200
  Clarendon Street, 54th Floor

  	
   

  
	
   

  	
  Boston,
  MA 02116

  	
   

  
						

 

SIGNATURE PAGE TO ARYx
THERAPEUTICS, INC.

BRIDGE INTELLECTUAL
PROPERTY SECURITY AGREEMENT

 

 

Exhibit A

 

COPYRIGHTS

 

1.                                       REGISTERED:
List titles below or indicate “None”

 

None.

 

2.                                       UNREGISTERED:
List titles below or indicate “None”

 

None.

 

3.                                       APPLICATIONS IN
PROCESS: List titles, applicable dates, application numbers, etc. below or
indicate “None”

 

None.

 

 

Exhibit
B

 

PATENTS

 

	
  Title

  	
   

  	
  Materials and Methods for the Treatment of Depression

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application
  No.

  	
   

  	
  Filing
  Date

  	
   

  	
  Patent
  No.

  	
   

  	
  Issue
  Date

  	
   

  	
  Expiration Date

  
	
  04-1009

  	
   

  	
  E

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2001255654

  	
   

  	
  24-Apr-2001

  	
   

  	
  2001255654

  	
   

  	
  6-Jan-2006

  	
   

  	
  24-Apr-2021

  
	
  04-1009

  	
   

  	
  F

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2405025

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1009

  	
   

  	
  G

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1928840.6

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1009

  	
   

  	
  H

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2001-577944

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1009

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Expired

  	
   

  	
  60/199343

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2001

  
	
  04-1009

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/841749

  	
   

  	
  24-Apr-2001

  	
   

  	
  6469064

  	
   

  	
  22-Oct-2002

  	
   

  	
  24-Apr-2021

  
	
  04-1009

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/273702

  	
   

  	
  18-Oct-2002

  	
   

  	
  6809116

  	
   

  	
  26-Oct-2004

  	
   

  	
  24-Apr-2021

  
	
  04-1009

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  10/931586

  	
   

  	
  31-Aug-2004

  	
   

  	
  7256191

  	
   

  	
  14-Aug-2007

  	
   

  	
  22-Dec-2023

  
	
  04-1009

  	
   

  	
  D

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/13275

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1009

  	
   

  	
  I

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Abandoned

  	
   

  	
  US05/29868

  	
   

  	
  23-Aug-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Novel compounds for treatment of cardiac arrhythmia,
  synthesis, and methods of use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1010

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2002360582

  	
   

  	
  10-Dec-2002

  	
   

  	
  2002360582

  	
   

  	
  24-Sep-2009

  	
   

  	
  10-Dec-2022

  
	
  04-1010

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2469730

  	
   

  	
  10-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1010

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2795850.3

  	
   

  	
  10-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1010

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2003-551127

  	
   

  	
  10-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1010

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/339898

  	
   

  	
  10-Dec-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10-Dec-2002

  
	
  04-1010

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/319073

  	
   

  	
  10-Dec-2002

  	
   

  	
  6710070

  	
   

  	
  23-Mar-2004

  	
   

  	
  10-Dec-2022

  
	
  04-1010

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/799546

  	
   

  	
  11-Mar-2004

  	
   

  	
  6869972

  	
   

  	
  22-Mar-2005

  	
   

  	
   

  
	
  04-1010

  	
   

  	
  B1

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/074152

  	
   

  	
  7-Mar-2005

  	
   

  	
  7037933

  	
   

  	
  2-May-2006

  	
   

  	
  11-Mar-2024

  
	
  04-1010

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US02/39849

  	
   

  	
  10-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Ultrashort Acting Hypnotic Barbiturates

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1011

  	
   

  	
  E

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2001257230

  	
   

  	
  24-Apr-2001

  	
   

  	
  2001257230

  	
   

  	
  5-Jan-2007

  	
   

  	
  24-Apr-2021

  
	
  04-1011

  	
   

  	
  F

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2404898

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

 

 

	
  04-1011

  	
   

  	
  G

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1930722.2

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1011

  	
   

  	
  H

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2001-578413

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1011

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/199144

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2001

  
	
  04-1011

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/841738

  	
   

  	
  24-Apr-2001

  	
   

  	
  6387914

  	
   

  	
  14-May-2002

  	
   

  	
  24-Apr-2021

  
	
  04-1011

  	
   

  	
  A-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Unfiled

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1011

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  10/145601

  	
   

  	
  13-May-2002

  	
   

  	
  6683086

  	
   

  	
  27-Jan-2004

  	
   

  	
  24-Apr-2021

  
	
  04-1011

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/763904

  	
   

  	
  23-Jan-2004

  	
   

  	
  7041673

  	
   

  	
  9-May-2006

  	
   

  	
  21-Jul-2022

  
	
  04-1011

  	
   

  	
  C-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Granted

  	
   

  	
  12/009446

  	
   

  	
  20-Dec-2007

  	
   

  	
  RE41289E

  	
   

  	
  27-Apr-2010

  	
   

  	
  23-Jan-2024

  
	
  04-1011

  	
   

  	
  D

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US01/13246

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Non-Oxidatively Metabolized Compounds and Compositions,
  Synthetic Pathways Therefore, and Uses Thereof

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1015

  	
   

  	
  C

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002331749

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  D

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2457532

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  E

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2768732.6

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  F

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2003-522469

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/314792

  	
   

  	
  24-Aug-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Aug-2002

  
	
  04-1015

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  10/228670

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  A1

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Transfered

  	
   

  	
  11/330881

  	
   

  	
  12-Jan-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1015

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/27298

  	
   

  	
  26-Aug-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Benzofuranyl Derivatives Useful For The Treatment Of Cardiac
  Arrhythmia

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1026

  	
   

  	
  B1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2005232701

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B2

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  PI0509740-1

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B3

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2560336

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B4

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  200580012140.X

  	
   

  	
  8-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B5

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  5735166

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B4-HK

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Abandoned

  	
   

  	
  7111251.4

  	
   

  	
  18-Oct-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B7

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  178127

  	
   

  	
  14-Sep-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B6

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2686/KOLNP/2007

  	
   

  	
  15-Sep-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B8

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2007-507557

  	
   

  	
  6-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B14

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2006-7022953

  	
   

  	
  1-Nov-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B9

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  PA/a/2006/011647

  	
   

  	
  6-Oct-2006

  	
   

  	
  261929

  	
   

  	
  5-Nov-2008

  	
   

  	
  8-Apr-2025

  
	
  04-1026

  	
   

  	
  B10

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20065156

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B11

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2006-501990

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-1026

  	
   

  	
  B12

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006139649

  	
   

  	
  8-Nov-2006

  	
   

  	
  2373199

  	
   

  	
  20-Nov-2009

  	
   

  	
  8-Apr-2025

  
	
  04-1026

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/560917

  	
   

  	
  9-Apr-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  9-Apr-2005

  
	
  04-1026

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/101995

  	
   

  	
  8-Apr-2005

  	
   

  	
  7105568

  	
   

  	
  12-Sep-2006

  	
   

  	
  8-Apr-2025

  
	
  04-1026

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/423559

  	
   

  	
  12-Jun-2006

  	
   

  	
  7351842

  	
   

  	
  1-Apr-2008

  	
   

  	
  8-Apr-2025

  
	
  04-1026

  	
   

  	
  C-DIV

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Published

  	
   

  	
  11/936620

  	
   

  	
  7-Nov-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US05/12138

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1026

  	
   

  	
  B13

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006/07666

  	
   

  	
  8-Apr-2005

  	
   

  	
  2006/07666

  	
   

  	
  26-Mar-2008

  	
   

  	
  8-Apr-2025

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Analgesic Delivery Systems and Methods of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1027

  	
   

  	
  C

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002361709

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
  D

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2469200

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
  E

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2797347.8

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
  F

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2003-552296

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/341743

  	
   

  	
  17-Dec-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17-Dec-2002

  
	
  04-1027

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  RCE

  	
   

  	
  Transfered

  	
   

  	
  10/321410

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1027

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/40183

  	
   

  	
  17-Dec-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for the Treatment of Hypertension and
  Angina

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1028

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002337842

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1028

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2462913

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1028

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2773743.6

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1028

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2003-534399

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1028

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/328588

  	
   

  	
  10-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10-Oct-2002

  
	
  04-1028

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/269139

  	
   

  	
  10-Oct-2002

  	
   

  	
  6608097

  	
   

  	
  19-Aug-2003

  	
   

  	
  10-Oct-2022

  
	
  04-1028

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/643699

  	
   

  	
  18-Aug-2003

  	
   

  	
  7265142

  	
   

  	
  4-Sep-2007

  	
   

  	
  10-Oct-2022

  
	
  04-1028

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/32562

  	
   

  	
  10-Oct-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for Treating Hypercholesterolemia

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1029

  	
   

  	
  B3

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2003259188

  	
   

  	
  18-Jan-2005

  	
   

  	
   

  	
   

  	
  19-Jun-2008

  	
   

  	
  21-Jul-2023

  

 

 

	
  04-1029

  	
   

  	
  B3-DIV

  	
   

  	
  AU

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  2008202241

  	
   

  	
  21-May-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
  B2

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2492906

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
  B1

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  3765847.3

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
  B4

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2004523222

  	
   

  	
  18-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/397076

  	
   

  	
  19-Jul-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-Jul-2003

  
	
  04-1029

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  10/624659

  	
   

  	
  21-Jul-2003

  	
   

  	
  6951877

  	
   

  	
  4-Oct-2005

  	
   

  	
  21-Jul-2023

  
	
  04-1029

  	
   

  	
  A1

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  11/220364

  	
   

  	
  6-Sep-2005

  	
   

  	
  7384973

  	
   

  	
  10-Jun-2008

  	
   

  	
  21-Jul-2023

  
	
  04-1029

  	
   

  	
  A1-DIV

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  12/027552

  	
   

  	
  7-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1029

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US03/022756

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Novel anticholinergic compounds for the treatment of
  incontinence

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1030

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002307118

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2443346

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2774092.7

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2003-500035

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/281134

  	
   

  	
  3-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  3-Apr-2002

  
	
  04-1030

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/350516

  	
   

  	
  18-Jan-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18-Jan-2003

  
	
  04-1030

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  10/116202

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1030

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/10614

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  5-HT3 Receptor Antagonists and Methods of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1031

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2003210610

  	
   

  	
  21-Jan-2003

  	
   

  	
  2003210610

  	
   

  	
  13-Mar-2008

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2473392

  	
   

  	
  21-Jan-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1031

  	
   

  	
  F1

  	
   

  	
  DE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F2

  	
   

  	
  ES

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F3

  	
   

  	
  FR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F4

  	
   

  	
  GB

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  F5

  	
   

  	
  IT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  3732034.8

  	
   

  	
  21-Jan-2003

  	
   

  	
  1465629

  	
   

  	
  14-Mar-2007

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2003-561601

  	
   

  	
  21-Jan-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1031

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/350504

  	
   

  	
  18-Jan-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18-Jan-2003

  
	
  04-1031

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/348669

  	
   

  	
  21-Jan-2003

  	
   

  	
  6770655

  	
   

  	
  3-Aug-2004

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Abandoned

  	
   

  	
  10/857108

  	
   

  	
  28-May-2004

  	
   

  	
  7125886

  	
   

  	
  24-Oct-2006

  	
   

  	
  25-Jun-2023

  

 

 

	
  04-1031

  	
   

  	
  B-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Unfiled

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1031

  	
   

  	
  B1

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/551562

  	
   

  	
  20-Oct-2006

  	
   

  	
  7501436

  	
   

  	
  10-Mar-2009

  	
   

  	
  21-Jan-2023

  
	
  04-1031

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US03/01876

  	
   

  	
  21-Jan-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Compound for Treatment of Cardiac Arrhythmia, Synthesis and
  Method of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1032

  	
   

  	
  F

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  71102/94

  	
   

  	
  16-Jun-1994

  	
   

  	
  697687

  	
   

  	
  28-Jan-1999

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  K

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2002211479

  	
   

  	
  4-Oct-2001

  	
   

  	
  2002211479

  	
   

  	
  13-Dec-2007

  	
   

  	
  4-Oct-2021

  
	
  04-1032

  	
   

  	
  G

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2164633

  	
   

  	
  16-Jun-1994

  	
   

  	
  2164633

  	
   

  	
  28-Nov-2006

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  G1

  	
   

  	
  CA

  	
   

  	
  DIV

  	
   

  	
  Transfered

  	
   

  	
  2566543

  	
   

  	
  16-Jun-1994

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  L

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2425245

  	
   

  	
  4-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  H2

  	
   

  	
  DE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  69407785.2

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  H

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  M

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1979531.9

  	
   

  	
  4-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  H1

  	
   

  	
  FR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  H3

  	
   

  	
  GB

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  N

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  480CHENP/2003

  	
   

  	
  4-Apr-2003

  	
   

  	
  209636

  	
   

  	
  5-Sep-2007

  	
   

  	
  4-Oct-2021

  
	
  04-1032

  	
   

  	
  H4

  	
   

  	
  IT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  I

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  7-502201

  	
   

  	
  16-Jun-1994

  	
   

  	
  3435411

  	
   

  	
  6-Jun-2003

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
  O

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2002-541092

  	
   

  	
  4-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  H5

  	
   

  	
  NL

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  94920234.5

  	
   

  	
  16-Jun-1994

  	
   

  	
  703910

  	
   

  	
  7-Jan-1998

  	
   

  	
  16-Jun-2014

  
	
  04-1032

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  08/078371

  	
   

  	
  16-Jun-1993

  	
   

  	
  5364880

  	
   

  	
  15-Nov-1994

  	
   

  	
  16-Jun-2013

  
	
  04-1032

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  08/260869

  	
   

  	
  16-Jun-1994

  	
   

  	
  5440054

  	
   

  	
  8-Aug-1995

  	
   

  	
  16-Jun-2013

  
	
  04-1032

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  08/468602

  	
   

  	
  6-Jun-1995

  	
   

  	
  5849788

  	
   

  	
  15-Dec-1998

  	
   

  	
  15-Dec-2015

  
	
  04-1032

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  09/211246

  	
   

  	
  14-Dec-1998

  	
   

  	
  6130240

  	
   

  	
  10-Oct-2000

  	
   

  	
  16-Jun-2013

  
	
  04-1032

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  09/680880

  	
   

  	
  6-Oct-2000

  	
   

  	
  6316487

  	
   

  	
  13-Nov-2001

  	
   

  	
  16-Jun-2013

  
	
  04-1032

  	
   

  	
  E

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US94/06812

  	
   

  	
  16-Jun-1994

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1032

  	
   

  	
  J

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/31305

  	
   

  	
  4-Oct-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for the Treatment of Diabetes

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1036

  	
   

  	
  G1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2001259130

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2002327683

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  G2

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2402123

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H2

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2460150

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  G3

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1932617.2

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-1036

  	
   

  	
  H3

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2763686.9

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H4

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  00845DELNP04

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  G4

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2001-578420

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H5

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2003-528791

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H6

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2004-7004172

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H7

  	
   

  	
  NZ

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  532261

  	
   

  	
  20-Sep-2002

  	
   

  	
  532261

  	
   

  	
  8-Jun-2006

  	
   

  	
  20-Sep-2022

  
	
  04-1036

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/199146

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2001

  
	
  04-1036

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/281982

  	
   

  	
  6-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  6-Apr-2002

  
	
  04-1036

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/297838

  	
   

  	
  13-Jun-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  13-Jun-2002

  
	
  04-1036

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/841351

  	
   

  	
  24-Apr-2001

  	
   

  	
  6680387

  	
   

  	
  20-Jan-2004

  	
   

  	
  24-Apr-2021

  
	
  04-1036

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  09/961542

  	
   

  	
  21-Sep-2001

  	
   

  	
  6768008

  	
   

  	
  27-Jul-2004

  	
   

  	
  24-Apr-2021

  
	
  04-1036

  	
   

  	
  E

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  10/251522

  	
   

  	
  20-Sep-2002

  	
   

  	
  6958355

  	
   

  	
  25-Oct-2005

  	
   

  	
  25-Sep-2021

  
	
  04-1036

  	
   

  	
  E1

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  11/167925

  	
   

  	
  27-Jun-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  F

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  10/759617

  	
   

  	
  16-Jan-2004

  	
   

  	
  7022722

  	
   

  	
  4-Apr-2006

  	
   

  	
  20-Nov-2021

  
	
  04-1036

  	
   

  	
  G

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/13131

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/30017

  	
   

  	
  20-Sep-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1036

  	
   

  	
  H8

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2004/1945

  	
   

  	
  20-Sep-2002

  	
   

  	
  2004/1945

  	
   

  	
  27-Jul-2005

  	
   

  	
  20-Sep-2022

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Isoxazolidine Compounds Useful in the Treatment of
  Diabetes, Hyperlipidemia, and Atherosclerosis in Mammals

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-1038

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/234423

  	
   

  	
  21-Sep-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  21-Sep-2001

  
	
  04-1038

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/961538

  	
   

  	
  21-Sep-2001

  	
   

  	
  6784199

  	
   

  	
  31-Aug-2004

  	
   

  	
  29-Oct-2021

  
	
  04-1038

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Transfered

  	
   

  	
  10/869516

  	
   

  	
  15-Jun-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-1038

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/29853

  	
   

  	
  21-Sep-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for the Treatment of Gastroesophageal
  Reflux Disease

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-882

  	
   

  	
  D

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  20012575326

  	
   

  	
  7-Jun-2001

  	
   

  	
  2001275326

  	
   

  	
  19-May-2006

  	
   

  	
  7-Jun-2021

  
	
  04-882

  	
   

  	
  D1

  	
   

  	
  AU

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  2006201053

  	
   

  	
  19-May-2006

  	
   

  	
  2006201053

  	
   

  	
  19-May-2006

  	
   

  	
  7-Jun-2021

  
	
  04-882

  	
   

  	
  E

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2410939

  	
   

  	
  7-Jun-2001

  	
   

  	
  2410939

  	
   

  	
  16-Feb-2010

  	
   

  	
  7-Jun-2021

  
	
  04-882

  	
   

  	
  F

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  1942028

  	
   

  	
  7-Jun-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-882

  	
   

  	
  G

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2002-501422

  	
   

  	
  7-Jun-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-882

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/209926

  	
   

  	
  7-Jun-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7-Jun-2001

  
	
  04-882

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/876698

  	
   

  	
  7-Jun-2001

  	
   

  	
  6552046

  	
   

  	
  22-Apr-2003

  	
   

  	
  7-Jun-2021

  

 

 

	
  04-882

  	
   

  	
  A-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Pending

  	
   

  	
  11/962592

  	
   

  	
  21-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-882

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Transfered

  	
   

  	
  10/418842

  	
   

  	
  18-Apr-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-882

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US01/18365

  	
   

  	
  7-Jun-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for Treating Coagulation Disorders

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-883

  	
   

  	
  B5-AT

  	
   

  	
  AT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2005233614

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-BE

  	
   

  	
  BE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B2

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  PI0508392-3

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B3

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2559568

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-CH

  	
   

  	
  CH

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B4

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2.0058E+11

  	
   

  	
  8-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-CY

  	
   

  	
  CY

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-DE

  	
   

  	
  DE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-DK

  	
   

  	
  DK

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  DK/EP1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-DIV

  	
   

  	
  EP

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  9175606.4

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-ES

  	
   

  	
  ES

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  2340690

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-FI

  	
   

  	
  FI

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-FR

  	
   

  	
  FR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-GB

  	
   

  	
  GB

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-GR

  	
   

  	
  GR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-DIVHK

  	
   

  	
  HK

  	
   

  	
  REP

  	
   

  	
  Pending

  	
   

  	
  10103549.8

  	
   

  	
  12-Apr-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B6

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Pending

  	
   

  	
  7110493.4

  	
   

  	
  27-Sep-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-IE

  	
   

  	
  IE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B8

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  178122

  	
   

  	
  14-Sep-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B8-DIV

  	
   

  	
  IL

  	
   

  	
  DIV

  	
   

  	
  Unfiled

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B7

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2793/KOLNP/2006

  	
   

  	
  25-Sep-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-IT

  	
   

  	
  IT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B9

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2007-507551

  	
   

  	
  6-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B15

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2006-7022954

  	
   

  	
  1-Nov-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-LU

  	
   

  	
  LU

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-MC

  	
   

  	
  MC

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B10

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  PA/a/2006/011637

  	
   

  	
  6-Oct-2006

  	
   

  	
  274321

  	
   

  	
  3-Mar-2010

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B5-NL

  	
   

  	
  NL

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B11

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20065079

  	
   

  	
  3-Nov-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B12

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2006-501866

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-883

  	
   

  	
  B5-PT

  	
   

  	
  PT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B13

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006139140

  	
   

  	
  7-Nov-2006

  	
   

  	
  2335501

  	
   

  	
  10-Oct-2008

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  B13-DIV

  	
   

  	
  RU

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  2008120295

  	
   

  	
  21-May-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B5-SE

  	
   

  	
  SE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5733799

  	
   

  	
  8-Apr-2005

  	
   

  	
  1735296

  	
   

  	
  9-Dec-2009

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/561121

  	
   

  	
  8-Apr-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  8-Apr-2005

  
	
  04-883

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/101714

  	
   

  	
  8-Apr-2005

  	
   

  	
  7253208

  	
   

  	
  7-Aug-2007

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  C

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/467813

  	
   

  	
  28-Aug-2006

  	
   

  	
  7285671

  	
   

  	
  23-Oct-2007

  	
   

  	
  8-Apr-2025

  
	
  04-883

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/778482

  	
   

  	
  16-Jul-2007

  	
   

  	
  7666902

  	
   

  	
  23-Feb-2010

  	
   

  	
  28-Aug-2026

  
	
  04-883

  	
   

  	
  D-CON

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Published

  	
   

  	
  12/268109

  	
   

  	
  10-Nov-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US05/12091

  	
   

  	
  8-Apr-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-883

  	
   

  	
  B14

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006/07667

  	
   

  	
  8-Apr-2005

  	
   

  	
  2006/07667

  	
   

  	
  28-Nov-2007

  	
   

  	
  8-Apr-2025

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Materials and Methods for Treating Coagulation Disorders

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-884

  	
   

  	
  G-AT

  	
   

  	
  AT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  E

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2002256361

  	
   

  	
  24-Apr-2002

  	
   

  	
  2002256361

  	
   

  	
  15-May-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-BE

  	
   

  	
  BE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  F

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2445160

  	
   

  	
  24-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  G-CH

  	
   

  	
  CH

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-CY

  	
   

  	
  CY

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-DE

  	
   

  	
  DE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-DK

  	
   

  	
  DK

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-ES

  	
   

  	
  ES

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-FI

  	
   

  	
  FI

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-FR

  	
   

  	
  FR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-GB

  	
   

  	
  GB

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-GR

  	
   

  	
  GR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-IE

  	
   

  	
  IE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-IT

  	
   

  	
  IT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  H

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2002-583409

  	
   

  	
  24-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  H-DIV

  	
   

  	
  JP

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  2010-16130

  	
   

  	
  27-Jan-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  G-LU

  	
   

  	
  LU

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-MC

  	
   

  	
  MC

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-NL

  	
   

  	
  NL

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-PT

  	
   

  	
  PT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-SE

  	
   

  	
  SE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  G-TR

  	
   

  	
  TR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  2725817.7

  	
   

  	
  24-Apr-2002

  	
   

  	
  1383756

  	
   

  	
  5-Mar-2008

  	
   

  	
  24-Apr-2022

  

 

 

	
  04-884

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/199143

  	
   

  	
  24-Apr-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2001

  
	
  04-884

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/286079

  	
   

  	
  24-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  24-Apr-2002

  
	
  04-884

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/132750

  	
   

  	
  24-Apr-2002

  	
   

  	
  6864279

  	
   

  	
  8-Mar-2005

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  B-REI

  	
   

  	
  US

  	
   

  	
  REI

  	
   

  	
  Unfiled

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  10/822129

  	
   

  	
  8-Apr-2004

  	
   

  	
  7145020

  	
   

  	
  5-Dec-2006

  	
   

  	
  24-Apr-2022

  
	
  04-884

  	
   

  	
  D1

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Abandoned

  	
   

  	
  11/551302

  	
   

  	
  20-Oct-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  D1-DIV

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Abandoned

  	
   

  	
  12/125623

  	
   

  	
  22-May-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-884

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/13163

  	
   

  	
  24-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Ultrashort-Acting Opioids for Transdermal Application

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-970

  	
   

  	
  C

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2002258714

  	
   

  	
  3-Apr-2002

  	
   

  	
  2002258714

  	
   

  	
  26-Jul-2007

  	
   

  	
  3-Apr-2022

  
	
  04-970

  	
   

  	
  D

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Transfered

  	
   

  	
  2443350

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-970

  	
   

  	
  E

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2728672.3

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-970

  	
   

  	
  F

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2002-592864

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-970

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/281080

  	
   

  	
  3-Apr-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  3-Apr-2002

  
	
  04-970

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  10/116320

  	
   

  	
  3-Apr-2002

  	
   

  	
  6686377

  	
   

  	
  3-Feb-2004

  	
   

  	
  3-Apr-2022

  
	
  04-970

  	
   

  	
  G

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/771483

  	
   

  	
  2-Feb-2004

  	
   

  	
  7001915

  	
   

  	
  21-Feb-2006

  	
   

  	
  3-Apr-2022

  
	
  04-970

  	
   

  	
  H

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  11/257323

  	
   

  	
  24-Oct-2005

  	
   

  	
  7381735

  	
   

  	
  3-Jun-2008

  	
   

  	
  23-Sep-2024

  
	
  04-970

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US02/10620

  	
   

  	
  3-Apr-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Novel Xanthines Having Adenosine A1-Receptor Antagonist
  Properties

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-971

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/397099

  	
   

  	
  19-Jul-2002

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-Jul-2003

  
	
  04-971

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  10/624713

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-971

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US03/22785

  	
   

  	
  21-Jul-2003

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Synthetic Methods and Intermediates for Steroisomeric
  Compounds useful for the Treatment of Gastrointestinal and Central Nervous
  System Disorders

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-972

  	
   

  	
  C5-AT

  	
   

  	
  AT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2005205531

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C1-DIV1

  	
   

  	
  AU

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  2008243243

  	
   

  	
  13-Nov-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-972

  	
   

  	
  J-AU

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2006284601

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-BE

  	
   

  	
  BE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C2

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  PI0506736-7

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-BR

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  PI0615691-6

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C3

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2551686

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H-CA

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2612893

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-CA

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2620379

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-CH

  	
   

  	
  CH

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C4

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0058E+11

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C4-DIV

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2.0101E+11

  	
   

  	
  8-Apr-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H-CN

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0068E+11

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-CN

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0068E+11

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-CY

  	
   

  	
  CY

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-DE

  	
   

  	
  DE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-DK

  	
   

  	
  DK

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-DIV

  	
   

  	
  EP

  	
   

  	
  DIV

  	
   

  	
  Published

  	
   

  	
  10153093.9

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H-EP

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Inactive

  	
   

  	
  6774511.7

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-EP

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  6802848.9

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-ES

  	
   

  	
  ES

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-FI

  	
   

  	
  FI

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-FR

  	
   

  	
  FR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-GB

  	
   

  	
  GB

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-GR

  	
   

  	
  GR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  J-CN-HK

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Published

  	
   

  	
  9101838.5

  	
   

  	
  26-Feb-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-IE

  	
   

  	
  IE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C11

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  176569

  	
   

  	
  26-Jun-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-IL

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  189202

  	
   

  	
  3-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C7

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1767/KOLNP/2006

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-IN

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  928/KOLNP/2008

  	
   

  	
  3-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-IT

  	
   

  	
  IT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C6

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2006-549435

  	
   

  	
  6-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H-JP

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Abandoned

  	
   

  	
  2008-520356

  	
   

  	
  4-Jan-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-JP

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2008-529331

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C10

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2006-7015208

  	
   

  	
  27-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-KR

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2008-7007843

  	
   

  	
  31-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-LU

  	
   

  	
  LU

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C5-MC

  	
   

  	
  MC

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C8

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  PA/a/2006/007853

  	
   

  	
  7-Jul-2006

  	
   

  	
  261425

  	
   

  	
  16-Oct-2008

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C8-DIV

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  MX/a/2008/013107

  	
   

  	
  10-Oct-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  04-972

  	
   

  	
  H-MX

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  MX/a/2007/016373

  	
   

  	
  18-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-MX

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  Mx/a/2008/002666

  	
   

  	
  31-Aug-2006

  	
   

  	
  273587

  	
   

  	
  25-Jan-2010

  	
   

  	
  31-Aug-2026

  
	
  04-972

  	
   

  	
  J-MX-DIV

  	
   

  	
  MX

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  MX/a/2010/000896

  	
   

  	
  22-Jan-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-NL

  	
   

  	
  NL

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C14

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20063568

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-NO

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20081562

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C12

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2006-501306

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C12-DIV

  	
   

  	
  PH

  	
   

  	
  DIV

  	
   

  	
  Pending

  	
   

  	
  1-2010-500400

  	
   

  	
  19-Feb-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J-PH

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2008-500353

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-PT

  	
   

  	
  PT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  C9

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006128589

  	
   

  	
  4-Aug-2006

  	
   

  	
  2374244

  	
   

  	
  27-Nov-2009

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  J-RU

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2008112215

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C5-SE

  	
   

  	
  SE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  5705267.2

  	
   

  	
  7-Jan-2005

  	
   

  	
  1704146

  	
   

  	
  14-Apr-2010

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  J-SG

  	
   

  	
  SG

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  200801146-2

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/534892

  	
   

  	
  7-Jan-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7-Jan-2005

  
	
  04-972

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/560938

  	
   

  	
  9-Apr-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7-Jan-2005

  
	
  04-972

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/031623

  	
   

  	
  7-Jan-2005

  	
   

  	
  7176218

  	
   

  	
  13-Feb-2007

  	
   

  	
  21-Aug-2025

  
	
  04-972

  	
   

  	
  D

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  11/087167

  	
   

  	
  23-Mar-2005

  	
   

  	
  7282509

  	
   

  	
  16-Oct-2007

  	
   

  	
  27-May-2025

  
	
  04-972

  	
   

  	
  E

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/696662

  	
   

  	
  5-Jul-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  5-Jul-2006

  
	
  04-972

  	
   

  	
  F

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/713149

  	
   

  	
  31-Aug-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  31-Aug-2006

  
	
  04-972

  	
   

  	
  F1

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/747762

  	
   

  	
  19-May-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-May-2007

  
	
  04-972

  	
   

  	
  G

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/805678

  	
   

  	
  23-Jun-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23-Jun-2007

  
	
  04-972

  	
   

  	
  H-US

  	
   

  	
  US

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  12/160655

  	
   

  	
  11-Jul-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  I

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/469264

  	
   

  	
  31-Aug-2006

  	
   

  	
  7326787

  	
   

  	
  5-Feb-2008

  	
   

  	
  31-Aug-2026

  
	
  04-972

  	
   

  	
  I-DIV

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Transfered

  	
   

  	
  11/950914

  	
   

  	
  5-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  I-DIV2

  	
   

  	
  US

  	
   

  	
  DIV

  	
   

  	
  Granted

  	
   

  	
  12/109500

  	
   

  	
  25-Apr-2008

  	
   

  	
  7629466

  	
   

  	
  8-Dec-2009

  	
   

  	
  5-Dec-2027

  
	
  04-972

  	
   

  	
  K

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Abandoned

  	
   

  	
  11/765554

  	
   

  	
  20-Jun-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  M

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Published

  	
   

  	
  11/778315

  	
   

  	
  16-Jul-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  N-PR

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/118079

  	
   

  	
  26-Nov-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26-Nov-2009

  
	
  04-972

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US05/00510

  	
   

  	
  7-Jan-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  H

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US06/26166

  	
   

  	
  5-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  J

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US06/34322

  	
   

  	
  31-Aug-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  L

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Abandoned

  	
   

  	
  PCT/US07/71685

  	
   

  	
  20-Jun-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  N-WO

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  PCT/US09/65925

  	
   

  	
  25-Nov-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-972

  	
   

  	
  C13

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2006/05308

  	
   

  	
  7-Jan-2005

  	
   

  	
  2006/05308

  	
   

  	
  31-Oct-2007

  	
   

  	
  7-Jan-2025

  
	
  04-972

  	
   

  	
  J-ZA

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2008/01144

  	
   

  	
  31-Aug-2006

  	
   

  	
  2008/01144

  	
   

  	
  28-Jan-2009

  	
   

  	
  31-Aug-2026

  

 

 

	
  Title

  	
   

  	
  Novel Enantiomeric Compounds For Treatment Of Cardiac
  Arrhythmia And Methods Of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-975

  	
   

  	
  D

  	
   

  	
  AR

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  P000105424

  	
   

  	
  13-Oct-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-AT

  	
   

  	
  AT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C1

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  10912/01

  	
   

  	
  13-Oct-2000

  	
   

  	
  774873

  	
   

  	
  21-Oct-2004

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-BE

  	
   

  	
  BE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C2

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2392016

  	
   

  	
  13-Oct-2000

  	
   

  	
  2392016

  	
   

  	
  13-Apr-2010

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C2-DIV

  	
   

  	
  CA

  	
   

  	
  DIV

  	
   

  	
  Closed

  	
   

  	
  tbd

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-CH

  	
   

  	
  CH

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-CY

  	
   

  	
  CY

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-DE

  	
   

  	
  DE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  60035888.7

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-DK

  	
   

  	
  DK

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C7

  	
   

  	
  EP

  	
   

  	
  DIV

  	
   

  	
  Published

  	
   

  	
  7011241.2

  	
   

  	
  13-Oct-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-ES

  	
   

  	
  ES

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-FI

  	
   

  	
  FI

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-FR

  	
   

  	
  FR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-GB

  	
   

  	
  GB

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-GR

  	
   

  	
  GR

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C6

  	
   

  	
  HK

  	
   

  	
  REP

  	
   

  	
  Granted

  	
   

  	
  3100473.3

  	
   

  	
  3-Dec-2007

  	
   

  	
  1049829

  	
   

  	
  22-Feb-2008

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C7-HK

  	
   

  	
  HK

  	
   

  	
  REP

  	
   

  	
  Published

  	
   

  	
  8101920.5

  	
   

  	
  22-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-IE

  	
   

  	
  IE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-IT

  	
   

  	
  IT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C5

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2001-531818

  	
   

  	
  13-Oct-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  C3-LU

  	
   

  	
  LU

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-MC

  	
   

  	
  MC

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-NL

  	
   

  	
  NL

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-PT

  	
   

  	
  PT

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  C3-SE

  	
   

  	
  SE

  	
   

  	
  EPP

  	
   

  	
  Granted

  	
   

  	
  972216.6

  	
   

  	
  13-Oct-2000

  	
   

  	
  1222180

  	
   

  	
  8-Aug-2007

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Transfered

  	
   

  	
  10/989010

  	
   

  	
  15-Nov-2004

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  04-975

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/680873

  	
   

  	
  6-Oct-2000

  	
   

  	
  6372783

  	
   

  	
  16-Apr-2002

  	
   

  	
  6-Oct-2020

  
	
  04-975

  	
   

  	
  B

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/684046

  	
   

  	
  6-Oct-2000

  	
   

  	
  6362223

  	
   

  	
  26-Mar-2003

  	
   

  	
  6-Oct-2020

  
	
  04-975

  	
   

  	
  E

  	
   

  	
  US

  	
   

  	
  CIP

  	
   

  	
  Granted

  	
   

  	
  10/123573

  	
   

  	
  15-Apr-2002

  	
   

  	
  6683195

  	
   

  	
  27-Jan-2004

  	
   

  	
  13-Oct-2020

  
	
  04-975

  	
   

  	
  F

  	
   

  	
  US

  	
   

  	
  CON

  	
   

  	
  Granted

  	
   

  	
  10/697683

  	
   

  	
  29-Oct-2003

  	
   

  	
  6818782

  	
   

  	
  16-Nov-2004

  	
   

  	
  15-Apr-2022

  
	
  04-975

  	
   

  	
  PRO1

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/159609

  	
   

  	
  15-Oct-1999

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15-Oct-2000

  
	
  04-975

  	
   

  	
  PRO2

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/290089

  	
   

  	
  10-May-2001

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  10-May-2002

  
	
  04-975

  	
   

  	
  C

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Transfered

  	
   

  	
  US00/28636

  	
   

  	
  13-Oct-2000

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

 

	
  Title

  	
   

  	
  Novel Long-Acting Local Anesthetics

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  04-996

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/093018

  	
   

  	
  16-Jul-1998

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  16-Jul-1999

  
	
  04-996

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  09/356283

  	
   

  	
  16-Jul-1999

  	
   

  	
  6114344

  	
   

  	
  5-Sep-2000

  	
   

  	
  16-Jul-2019

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Antiarrhythmic Precursor Compounds, Methods Of Synthesis
  And Methods Of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  05-611

  	
   

  	
  EP-AT

  	
   

  	
  AT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  E446300

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-AU

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2006270086

  	
   

  	
  11-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-BE

  	
   

  	
  BE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-BR

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  PI0613047-0

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-CA

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2612599

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-CH

  	
   

  	
  CH

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-CN

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0068E+11

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-CY

  	
   

  	
  CY

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-DE

  	
   

  	
  DE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6.02006E+11

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-DK

  	
   

  	
  DK

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-EP

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-EP-D1

  	
   

  	
  EP

  	
   

  	
  DIV

  	
   

  	
  Published

  	
   

  	
  9012534.5

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-ES

  	
   

  	
  ES

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  2334712

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-FI

  	
   

  	
  FI

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-FR

  	
   

  	
  FR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-GB

  	
   

  	
  GB

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-GR

  	
   

  	
  GR

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  3070959

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  CN-HK

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Published

  	
   

  	
  8113439.4

  	
   

  	
  10-Dec-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-IE

  	
   

  	
  IE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-IL

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  187917

  	
   

  	
  5-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-IN

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  76/KOLNP/2008

  	
   

  	
  4-Jan-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-IT

  	
   

  	
  IT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-JP

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2008-521686

  	
   

  	
  11-Jan-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-KR

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2007-7031026

  	
   

  	
  31-Dec-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-LU

  	
   

  	
  LU

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-MC

  	
   

  	
  MC

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-MX

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  MX/a/2008/000497

  	
   

  	
  10-Jan-2008

  	
   

  	
  272977

  	
   

  	
  18-Dec-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  EP-NL

  	
   

  	
  NL

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
  WO-NO

  	
   

  	
  NO

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  20080828

  	
   

  	
  15-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-PH

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2007-502821

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-PT

  	
   

  	
  PT

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  

 

 

	
  05-611

  	
   

  	
  WO-RU

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2008105757

  	
   

  	
  14-Feb-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  EP-SE

  	
   

  	
  SE

  	
   

  	
  EPC

  	
   

  	
  Granted

  	
   

  	
  6787500.5

  	
   

  	
  14-Jul-2006

  	
   

  	
  1904502

  	
   

  	
  21-Oct-2009

  	
   

  	
  14-Jul-2026

  
	
  05-611

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/699780

  	
   

  	
  15-Jul-2005

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15-Jul-2006

  
	
  05-611

  	
   

  	
  A

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Granted

  	
   

  	
  11/457719

  	
   

  	
  14-Jul-2006

  	
   

  	
  7498449

  	
   

  	
  3-Mar-2009

  	
   

  	
  9-Feb-2027

  
	
  05-611

  	
   

  	
  B

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  US06/27599

  	
   

  	
  14-Jul-2006

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  05-611

  	
   

  	
  WO-ZA

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Granted

  	
   

  	
  2007/10688

  	
   

  	
  14-Jul-2006

  	
   

  	
  2007/10688

  	
   

  	
  30-Sep-2009

  	
   

  	
  14-Jul-2026

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  DIBENZO [b,f][1,4]OXAZAPINE COMPOUNDS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  06-834

  	
   

  	
  WO-AU

  	
   

  	
  AU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2008225014

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-BR

  	
   

  	
  BR

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  PI0808828-4

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-CA

  	
   

  	
  CA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2678897

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-CN

  	
   

  	
  CN

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  2.0088E+11

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-EP

  	
   

  	
  EP

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  8732129.5

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-CN-HK

  	
   

  	
  HK

  	
   

  	
  RCN

  	
   

  	
  Published

  	
   

  	
  10103213.3

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-IL

  	
   

  	
  IL

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  200250

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-IN

  	
   

  	
  IN

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  4967/CHENP/2009

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-JP

  	
   

  	
  JP

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2009-553781

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-KR

  	
   

  	
  KR

  	
   

  	
  PCT

  	
   

  	
  Published

  	
   

  	
  10-2009-7021464

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-MX

  	
   

  	
  MX

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  MX/a/2009/009535

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-PH

  	
   

  	
  PH

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  1-2009-501530

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-RU

  	
   

  	
  RU

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2009138039

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  TW

  	
   

  	
  TW

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  97109258

  	
   

  	
  14-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  60/895046

  	
   

  	
  15-Mar-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  15-Mar-2008

  
	
  06-834

  	
   

  	
  US

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  12/047858

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Entered Na

  	
   

  	
  PCT/US08/56866

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  06-834

  	
   

  	
  WO-ZA

  	
   

  	
  ZA

  	
   

  	
  PCT

  	
   

  	
  Pending

  	
   

  	
  2009/06573

  	
   

  	
  13-Mar-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  A Dispersion-Capped Polarizable Force Field For
  Hydrocarbons

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  07-302

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  60/910363

  	
   

  	
  5-Apr-2007

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  5-Apr-2008

  

 

 

	
  Title

  	
   

  	
  Utility of Genotyping in the First Evaluation of a Novel
  Vitamin K Antagonist

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  08-026

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Transfered

  	
   

  	
  61/019457

  	
   

  	
  7-Jan-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  7-Jan-2009

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Agonists of Peroxisome Proliferator Activated
  Receptor-Alpha

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  08-528

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/139012

  	
   

  	
  19-Dec-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-Dec-2009

  
	
  08-528

  	
   

  	
  PR2

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/139016

  	
   

  	
  19-Dec-2008

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  19-Dec-2009

  
	
  08-528

  	
   

  	
  PR3

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/287892

  	
   

  	
  18-Dec-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18-Dec-2010

  
	
  08-528

  	
   

  	
  US

  	
   

  	
  US

  	
   

  	
  ORD

  	
   

  	
  Pending

  	
   

  	
  12/641954

  	
   

  	
  18-Dec-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  08-528

  	
   

  	
  WO

  	
   

  	
  WO

  	
   

  	
  ORD

  	
   

  	
  Published

  	
   

  	
  PCT/US09/68763

  	
   

  	
  18-Dec-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Methods For Treating Atrial Fibrillation And Reducing
  Stroke Rate In Atrial Fibrillation Patients

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-1219

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/263465

  	
   

  	
  23-Nov-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23-Nov-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Methods For Stroke Reduction In Atrial Fibrillation
  Patients

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-1220

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/263564

  	
   

  	
  23-Nov-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23-Nov-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Methods For Treating Atrial Fibrillation

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-1221

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/263567

  	
   

  	
  23-Nov-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  23-Nov-2010

  

 

 

	
  Title

  	
   

  	
  Deuterium-Enriched Antiarrhythmic Compounds And
  Compositions

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-670

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/184582

  	
   

  	
  5-Jun-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  5-Jun-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  D2 Antagonists, Methods of Synthesis and Methods of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-698

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/187971

  	
   

  	
  17-Jun-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  17-Jun-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Localized Delivery of 5HT4 Agonists

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-734

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Inactive

  	
   

  	
  61/220798

  	
   

  	
  26-Jun-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  26-Jun-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Compounds For Treatment of Cardiac Arrhythmia, Synthesis
  And Methods Of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  09-949

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/242032

  	
   

  	
  14-Sep-2009

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  14-Sep-2010

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  D2 Antagonists, Methods Of Synthesis And Methods Of Use

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  10-776

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/356096

  	
   

  	
  18-Jun-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  18-Jun-2011

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Title

  	
   

  	
  Localized Delivery Of 5HT4 Agonists

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
  Case

  Number

  	
   

  	
  Sub

  Case

  	
   

  	
  Country

  	
   

  	
  Case

  Type

  	
   

  	
  Status

  	
   

  	
  Application No.

  	
   

  	
  Filing Date

  	
   

  	
  Patent No.

  	
   

  	
  Issue Date

  	
   

  	
  Expiration Date

  
	
  10-777

  	
   

  	
   

  	
   

  	
  US

  	
   

  	
  PRO

  	
   

  	
  Pending

  	
   

  	
  61/359435

  	
   

  	
  29-Jun-2010

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  29-Jun-2011

  

 

 

Exhibit C

 

U.S.
TRADEMARKS AND TRADEMARK APPLICATIONS

 

(List
marks below or indicate “None”)

 

	
  Registration
  No.

  	
   

  	
  Pending

  Application No.

  	
   

  	
  Mark

  	
   

  	
  Registration Date

  	
   

  	
  Filing Date

  
	
  None

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  

 

UNREGISTERED
TRADEMARKS: List marks below or indicate “None.”

 

None.EXHIBIT 10.4

 

REGISTRATION
RIGHTS AGREEMENT

 

This REGISTRATION
RIGHTS AGREEMENT (this “Agreement”)
is made as of the 13th day of August, 2010, by and among (i) ARYx
Therapeutics, Inc., a Delaware corporation (the “Company”),
(ii) each party listed on EXHIBIT A
attached hereto (collectively, the “Initial Investors”
and each individually, an “Initial Investor”),
and (iii) each person or entity that subsequently becomes a party to this
Agreement pursuant to, and in accordance with, the provisions of
Section 12 hereof (collectively, the “Investor Permitted
Transferees” and each individually an “Investor
Permitted Transferee”).

 

WHEREAS, the Company
has agreed to issue and sell to the Initial Investors, and the Initial
Investors have agreed to purchase from the Company, warrants (each a “Warrant” and together the “Warrants”) to purchase an aggregate
of two million (2,000,000) shares of Common Stock of the Company, $0.001 par
value per share (the “Common Stock”),
all upon  the terms and conditions set
forth in that certain Secured Note and Warrant Purchase Agreement, dated of
even date herewith, between the Company and the Initial Investors (the “Purchase Agreement”); and

 

WHEREAS, the terms of
the Purchase Agreement provide that it shall be a condition precedent to the
closing of the transactions thereunder, for the Company and the Initial
Investors to execute and deliver this Agreement.

 

NOW, THEREFORE, in
consideration of the premises and mutual covenants contained herein, the
parties hereto hereby agree as follows:

 

1.             DEFINITIONS.  The
following terms shall have the meanings provided therefor below or elsewhere in
this Agreement as described below:

 

“Board”
shall mean the board of directors of the Company.

 

“Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended,
and all of the rules and regulations promulgated thereunder.

 

“Initial
Closing” shall have the meaning ascribed to such term in the
Purchase Agreement.

 

“Investors”
shall mean, collectively, the Initial Investors and the Investor Permitted
Transferees; provided, however,
that the term “Investors “ shall not include
any of the Initial Investors or any of the Investor Permitted Transferees that
does not own or hold any Registrable Shares.

 

“Majority
Holders” shall mean, at the relevant time of reference thereto,
those Investors holding more than fifty percent (50%) of the Registrable Shares
held by all of the Investors.

 

“Qualifying
Holder” shall have the meaning ascribed thereto in
Section 12 hereof.

 

“Registrable
Shares” shall mean the Underlying Shares, provided,
however, such term shall not, after the
Mandatory Registration Termination Date, include any of the Underlying Shares
that become or have become eligible for resale without restrictions or volume
limitations pursuant to Rule 144 or as a result of a subsequent sale made
pursuant to Regulation S under the Securities Act.

 

“Rule 144”
shall mean Rule 144 promulgated under the Securities Act and any successor
or substitute rule, law or provision.

 

1

 

“SEC”
shall mean the Securities and Exchange Commission.

 

“Securities
Act” shall mean the Securities Act of 1933, as amended, and all
of the rules and regulations promulgated thereunder.

 

“Underlying
Shares” shall mean the shares of Common Stock issuable upon
exercise of the Warrants.

 

2.             EFFECTIVENESS; TERMINATION.  This
Agreement shall become effective and legally binding only if the Initial
Closing occurs.

 

3.             MANDATORY REGISTRATION.

 

(a)           Within sixty (60) days after
the Initial Closing, the Company will prepare and file with the SEC a
registration statement on Form S-3 (or such other form as may be then
available to the Company) for the purpose of registering under the Securities
Act all of the Registrable Shares for resale by, and for the account of, the
Investors as selling stockholders thereunder (the “Registration
Statement”). The Registration Statement shall permit the
Investors to offer and sell, on a delayed or continuous basis pursuant to
Rule 415 under the Securities Act, any or all of the Registrable Shares.
The Company agrees to use commercially reasonable best efforts to cause the
Registration Statement to become effective as soon as practicable, but in no
event later than ninety (90) days after the Initial Closing (or one hundred
twenty (120) days if the Registration Statement is reviewed by the SEC) (the “Effectiveness Deadline”).  In
the event that, after the Initial Closing and before the Registration Statement
is declared effective, there is an act of God, war or terror that has the
effect of causing a delay in the effectiveness of the Registration Statement,
the Effectiveness Deadline will be extended by a number of days equal to the
days of any such act, plus ten (10) additional days. Notwithstanding the
foregoing, if the Company is required to file the Registration Statement on a
Form S-1, then the Company shall have ninety (90) days from the Initial
Closing to prepare and file the Registration Statement and the Effectiveness
Deadline shall be, in such case, one hundred eighty (180) days after the
Initial Closing.

 

(b)           The Company shall be
required to keep the Registration Statement effective until such date that is
the earlier of (i) the date when all of the Registrable Shares registered
thereunder shall have been sold, or (ii) the date as of which all of the
Registrable Shares (excluding such Registrable Shares as are registered
pursuant to any other effective Registration Statement) are freely tradable
(without any restrictions or volume limitations) by the Investors pursuant to
Rule 144 promulgated under the Securities Act or any successor or
substitute rule, law or provision (such date is referred to herein as the “Mandatory Registration Termination Date”). 
Thereafter, the Company shall be entitled to withdraw the Registration
Statement and the Investors shall have no further right to offer or sell any of
the Registrable Shares pursuant to the Registration Statement (or any
prospectus relating thereto).

 

(c)           The offer and sale of the
Registrable Shares pursuant to the Registration Statement shall not be
underwritten.

 

4.             DEMAND REGISTRATION RIGHTS.

 

(a)           If a Registration Statement
covering the Registrable Shares is not filed with the SEC on or prior to sixty
(60) days after the Initial Closing (which shall be ninety (90) days from the
Initial Closing in the event the Company is required to file the Registration
Statement on a Form S-1) (the “Filing Deadline”)
or if, at any time prior to the Mandatory Registration Termination Date, the
Registration Statement is no longer effective, subject to the conditions set
forth in this Section 4, and the

 

2

 

Company shall have received
a written request from the Majority Holders that the Company file a
registration statement under the Securities Act covering the registration of
Registrable Shares then held by the Investors, then the Company shall, within
ten (10) business days of the receipt thereof, give written notice of such
request to all Investors, and subject to the limitations of this
Section 4, effect, as expeditiously as reasonably possible, the
registration under the Securities Act of all Registrable Shares that all
Investors request to be registered, which registration statement may require
the Company to use a Registration Statement on Form S-1.

 

(b)           The Company shall not be
required to effect a registration pursuant to this Section 4:

 

(i)            after the Company has
effected one registration pursuant to this Section 4; and

 

(ii)           if the Company shall furnish
to the Investors a certificate signed by the Chairman of the Board stating that
in the good faith judgment of the Board, it would be materially detrimental to
the Company and its stockholders for such registration statement to be effected
at such time because such action (x) would materially interfere with a
significant acquisition, corporate reorganization or financing or other similar
transaction involving the Company, (y) would require premature disclosure
of material information that the Company has a bona fide business purpose for
preserving as confidential (provided,
that no such information will be required to be disclosed to any of the
Investors) or (z) would render the Company unable to comply with
requirements under the Securities Act or Exchange Act, in which event the
Company shall have the right to defer such filing for a period of not more than
one hundred twenty (120) days after receipt of the request of the Majority
Holders; provided, that such
right to delay a request shall be exercised by the Company not more than once; provided, further, that the Company shall
not register any securities for the account of itself or any other
stockholder during such one hundred twenty (120) day period (other than
pursuant to a registration statement on Form S-4 or S-8).

 

5.             OBLIGATIONS OF THE COMPANY.  In
connection with the Company’s obligation under Section 3 and, if
applicable, Section 4 hereof to file a registration statement with the SEC
and to use its commercially reasonable efforts to cause such registration
statement to become effective, the Company shall, as expeditiously as
reasonably possible:

 

(a)           Prepare and file with the
SEC such amendments and supplements to the Registration Statement and the
prospectus used in connection therewith as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all
Registrable Shares covered by such registration statement;

 

(b)           Furnish to the selling
Investors such number of copies of a prospectus, including a preliminary
prospectus, in conformity with the requirements of the Securities Act, and such
other documents (including, without limitation, prospectus amendments and
supplements as are prepared by the Company in accordance with
Section 5(a) above) as the selling Investors may reasonably request
in order to facilitate the disposition of such selling Investors’ Registrable
Shares;

 

(c)           Notify the selling
Investors, at any time during which a prospectus relating to such registration
statement is required to be delivered under the Securities Act, of the
happening of any event as a result of which the prospectus included in or
relating to the registration statement contains an untrue statement of a
material fact or omits any fact necessary to make the statements therein not
misleading; and, thereafter, the Company will promptly prepare (and, when
completed, give notice and provide a copy thereof to each selling Investor) a
supplement or amendment to such prospectus so that, as thereafter delivered to
the purchasers of such Registrable Shares, such

 

3

 

prospectus will not contain
an untrue statement of a material fact or omit to state any fact necessary to
make the statements therein not misleading; provided  that upon such notification by the Company,
the selling Investors will not offer or sell Registrable Shares until the
Company has notified the selling Investors that it has prepared a supplement or
amendment to such prospectus and delivered copies of such supplement or
amendment to the selling Investors (it being understood and agreed by the
Company that the foregoing proviso shall in no way diminish or otherwise impair
the Company’s obligation to promptly prepare a prospectus amendment or
supplement as above provided in this Section 5(c) and deliver copies
of same as above provided in Section 5(b) hereof); and

 

(d)           Use commercially reasonable
efforts to register and qualify the Registrable Shares covered by such
registration statement under such other securities or Blue Sky laws of such states
and other jurisdictions as shall be reasonably appropriate in the opinion of
the Company and the managing underwriters, if any; provided  that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or
jurisdictions; provided, further  that (notwithstanding anything in this
Agreement to the contrary with respect to the bearing of expenses) if any
jurisdiction in which any of such Registrable Shares shall be qualified shall
require that expenses incurred in connection with the qualification therein of
any such Registrable Shares be borne by the selling Investors, then the selling
Investors shall, to the extent required by such jurisdiction, pay their pro
rata share of such qualification expenses.

 

(e)           Subject to the terms and
conditions of this Agreement, the Company shall use its commercially reasonable
efforts to (i) prevent the issuance of any stop order or other suspension
of effectiveness of a registration statement, or the suspension of the
qualification of any of the Registrable Shares for sale in any jurisdiction in
the United States, and (ii) if such an order or suspension is issued,
obtain the withdrawal of such order or suspension at the earliest practicable
moment and notify each holder of Registrable Shares of the issuance of such
order and the resolution thereof or its receipt of notice of the initiation or
threat of any proceeding for such purpose.

 

6.             FURNISH INFORMATION.  It
shall be a condition precedent to the obligations of the Company to take any
action pursuant to this Agreement that the selling Investors shall furnish to
the Company such information regarding them and the securities held by them as
the Company shall reasonably request and as shall be required in order to
effect any registration by the Company pursuant to this Agreement.  Each
Investor shall prior to the Effectiveness Deadline promptly notify the Company
of any changes in the information furnished to the Company.

 

7.             EXPENSES OF REGISTRATION.  Except
as set forth in Section 5(d), all expenses incurred in connection with the
registration of the Registrable Shares pursuant to this Agreement (excluding
underwriting, brokerage and other selling commissions and discounts), including
without limitation all registration and qualification and filing fees,
printing, and fees and disbursements of counsel for the Company, shall be borne
by the Company.

 

8.             DELAY OF REGISTRATION.  The
Investors shall not take any action to restrain, enjoin or otherwise delay any
registration as the result of any controversy which might arise with respect to
the interpretation or implementation of this Agreement.

 

9.             INDEMNIFICATION.

 

(a)           To the extent permitted by
law, the Company will indemnify and hold harmless each selling Investor, any
investment banking firm acting as an underwriter for the selling Investors, any
broker/dealer acting on behalf of any selling Investors and each officer,
director, partner,

 

4

 

manager and/or member of
such selling Investor, such underwriter, such broker/dealer and each person, if
any, who controls such selling Investor, such underwriter or broker/dealer
within the meaning of the Securities Act or the Exchange Act, against any
losses, claims, damages or liabilities, joint or several, to which they may
become subject under the Securities Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or
are based upon any untrue or alleged untrue statement of any material fact
contained in the Registration Statement, in any preliminary prospectus or final
prospectus relating thereto or in any amendments or supplements to the
Registration Statement or any such preliminary prospectus or final prospectus,
or arise out of or are based upon the omission or alleged omission to state
therein a material fact required to be stated therein, or necessary to make the
statements therein not misleading; and will reimburse such selling Investor,
such underwriter, broker/dealer or such officer, director or controlling person
for any legal or other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in
this Section 9(a) shall not apply to amounts paid in settlement of
any such loss, claim, damage, liability or action if such settlement is
effected without the consent of the Company (which consent shall not be
unreasonably withheld), nor shall the Company be liable in any such case for
any such loss, damage, liability or action to the extent that it arises out of
or is based upon (i) an untrue statement or alleged untrue statement or
omission made in connection with the Registration Statement, any preliminary
prospectus or final prospectus relating thereto or any amendments or
supplements to the Registration Statement or any such preliminary prospectus or
final prospectus, in reliance upon and in conformity with written information
furnished expressly for use in connection with the Registration Statement or
any such preliminary prospectus or final prospectus by the selling Investors or
(ii) an untrue statement or alleged untrue statement or omission in the
Registration Statement or any prospectus that is corrected in any subsequent
amendment or supplement to the Registration Statement or prospectus that was
delivered to the selling Investor before the pertinent sale or sales by the
selling Investor.

 

(b)           To the extent permitted by
law, each selling Investor will severally and not jointly indemnify and hold
harmless the Company, each of its directors, each of its officers who have
signed the Registration Statement, each person, if any, who controls the
Company within the meaning of the Securities Act or the Exchange Act, any
investment banking firm acting as underwriter for the Company or the selling
Investors, or any broker/dealer acting on behalf of the Company or any selling
Investors, and all other selling Investors against any losses, claims, damages
or liabilities to which the Company or any such director, officer, controlling
person, underwriter, or broker/dealer or such other selling Investor may become
subject to, under the Securities Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereto) arise out of or
are based upon any untrue or alleged untrue statement of any material fact
contained in the Registration Statement or any preliminary prospectus or final
prospectus, relating thereto or in any amendments or supplements to the
Registration Statement or any such preliminary prospectus or final prospectus,
or arise out of or are based upon the omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, in each case to the extent and only to the
extent that such untrue statement or alleged untrue statement or omission or
alleged omission (i) was made in the Registration Statement, in any
preliminary prospectus or final prospectus relating thereto or in any
amendments or supplements to the Registration Statement or any such preliminary
prospectus or final prospectus, in reliance upon and in conformity with written
information furnished by the selling Investor expressly for use in connection
with the Registration Statement or any such preliminary prospectus or final
prospectus or (ii) was corrected in any subsequent amendment or supplement
to the Registration Statement or prospectus that was delivered to the selling
Investor before the pertinent sale or sales by the selling Investor and such
corrected amendment or supplement to the Registration Statement or prospectus
was not delivered to the purchaser; and such selling Investor will reimburse
any legal or other expenses reasonably incurred by the Company or any such
director, officer, controlling person, underwriter, broker/dealer or other
selling Investor in connection with investigating or defending any such loss,
claim,

 

5

 

damage, liability or action;
provided, however, that the liability of
each selling Investor hereunder shall be limited to the proceeds (net of
underwriting discounts and commissions, if any) received by such selling
Investor from the sale of Registrable Shares covered by the Registration
Statement; provided, further,  however,
that the indemnity agreement contained in this Section 9(b) shall not
apply to amounts paid in settlement of any such loss, claim, damage, liability
or action if such settlement is effected without the consent of those selling
Investor(s) against which the request for indemnity is being made (which
consent shall not be unreasonably withheld).

 

(c)           Promptly after receipt by an
indemnified party under this Section 9 of notice of the commencement of
any action, such indemnified party will, if a claim in respect thereof is to be
made against any indemnifying party under this Section 9, notify the indemnifying
party in writing of the commencement thereof and the indemnifying party shall
have the right to participate in and, to the extent the indemnifying party
desires, jointly with any other indemnifying party similarly noticed, to assume
at its expense the defense thereof with counsel mutually satisfactory to the
indemnifying parties and the indemnified parties.  In the event that the
indemnifying party assumes any such defense, the indemnified party may
participate in such defense with its own counsel and at its own expense; provided, however, that the counsel for the indemnifying
party shall act as lead counsel in all matters pertaining to such defense or
settlement of such claim and the indemnifying party shall only pay for such
indemnified party’s expenses for the period prior to the date of its
participation in such defense.  In any such proceeding, any indemnified
party shall have the right to retain its own counsel, but the fees and expenses
of such counsel shall be at the expense of such indemnified party unless
(i) the indemnifying party and the indemnified party shall have mutually
agreed to the retention of such counsel, (ii) the named parties to any
such proceeding (including any impleaded parties) include both the indemnifying
party and the indemnified party and the representation of both parties by the
same counsel would be inappropriate due to actual or potential differing
interests between them or (iii) the indemnifying party shall have failed
to retain counsel reasonably satisfactory to the indemnified party to represent
the indemnified party in any such proceeding. It is understood that the
indemnifying party shall not, in connection with any such proceeding or related
proceedings in the same jurisdiction, be liable for the fees and expenses of
more than one separate firm  (in addition to one local counsel in each
applicable jurisdiction) for all such indemnified parties and that all such
fees and expenses shall be reimbursed as they are incurred. The failure to
notify an indemnifying party promptly of the commencement of any such action,
if prejudicial to his ability to defend such action, shall relieve such
indemnifying party of any liability to the indemnified party under this
Section 9, but the omission so to notify the indemnifying party will not relieve
him of any liability which he may have to any indemnified party otherwise other
than under this Section 9.

 

(d)           Notwithstanding anything to
the contrary herein, the indemnifying party shall not be entitled to settle any
claim, suit or proceeding unless in connection with such settlement the
indemnified party receives an unconditional release with respect to the subject
matter of such claim, suit or proceeding and such settlement does not contain
any admission of fault by the indemnified party.

 

(e)           If the indemnification
provided for in this Section 9 is unavailable to or insufficient to hold
harmless an indemnified party under subsection (a) or (b) above in
respect of any losses, claims, damages or liabilities (or actions or proceedings
in respect thereof) referred to therein, then each indemnifying party shall
contribute to the amount paid or payable by such indemnified party as a result
of such losses, claims, damages or liabilities (or actions in respect thereof)
in such proportion as is appropriate to reflect the relative fault of the
Company on the one hand and the Investors on the other in connection with the
statements or omissions or other matters which resulted in such losses, claims,
damages or liabilities (or actions in respect thereof), as well as any other
relevant equitable considerations.  The relative fault shall be determined
by reference to, among other things, in the case of an untrue statement,
whether the untrue statement relates to information supplied by the Company on
the

 

6

 

one hand or an Investor on
the other and the parties’ relative intent, knowledge, access to information
and opportunity to correct or prevent such untrue statement. The Company and
the Investors agree that it would not be just and equitable if contribution
pursuant to this subsection (e) were determined by pro rata allocation
(even if the Investors were treated as one entity for such purpose) or by any
other method of allocation which does not take into account the equitable
considerations referred to above in this subsection (e).  The amount paid
or payable by an indemnified party as a result of the losses, claims, damages
or liabilities (or actions in respect thereof) referred to above in this
subsection (e) shall be deemed to include any legal or other expenses
reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim.  No person guilty of fraudulent
misrepresentation (within the meaning of Section 12(f) of the
Securities Act) shall be entitled to contribution from any person who was not
guilty of such fraudulent misrepresentation. The Investors’ obligations in this
subsection to contribute are several, and not joint, in proportion to their
sales of Registrable Shares to which such loss relates.

 

(f)            The parties to this
Agreement hereby acknowledge that they are sophisticated business persons who
were represented by counsel during the negotiations regarding the provisions
hereof including, without limitation, the provisions of this Section 9,
and are fully informed regarding said provisions.  They further
acknowledge that the provisions of this Section 9 fairly allocate the
risks in light of the ability of the parties to investigate the Company and its
business in order to assure that adequate disclosure is made in the
Registration Statement as required by the Securities Act and the Exchange Act.

 

10.           REPORTS UNDER THE EXCHANGE ACT.  With a
view to making available to the Investors the benefits of Rule 144 and any
other rule or regulation of the SEC that may at any time permit the
Investors to sell the Underlying Shares to the public without registration, the
Company agrees to use reasonable best efforts: (i) to make and keep public
information available as those terms are understood in Rule 144,
(ii) to file with the SEC in a timely manner all reports and other
documents required to be filed by an issuer of securities registered under the
Securities Act or the Exchange Act, (iii) as long as any Investor owns any
Registrable Shares, to furnish in writing upon such Investor’s request a
written statement by the Company that it has complied with the reporting
requirements of Rule 144 and of the Securities Act and the Exchange Act,
and to furnish to such Investor a copy of the most recent annual or quarterly
report of the Company, and such other reports and documents so filed by the
Company as may be reasonably requested in availing such Investor of any
rule or regulation of the SEC permitting the selling of any such
Registrable Shares without registration and (iv) undertake any additional
actions reasonably necessary to maintain the availability of the Registration
Statement or the use of Rule 144.

 

11.           SUSPENSION. 
Notwithstanding anything in this Agreement to the contrary, in the event
(i) of any request by the SEC or any other federal or state governmental
authority during the period of effectiveness of the Registration Statement for
amendments or supplements to a Registration Statement or related prospectus or
for additional information; (ii) of the issuance by the SEC or any other
federal or state governmental authority of any stop order suspending the
effectiveness of a Registration Statement or the initiation of any proceedings
for that purpose; (iii) of the receipt by the Company of any notification
with respect to the suspension of the qualification or exemption from
qualification of any of the Registrable Shares for sale in any jurisdiction or
the initiation of any proceeding for such purpose; (iv) of any event or
circumstance which necessitates the making of any changes in the Registration
Statement or related prospectus, or any document incorporated or deemed to be
incorporated therein by reference, so that, in the case of the Registration
Statement, it will not contain any untrue statement of a material fact or any
omission to state a material fact required to be stated therein or necessary to
make the statements therein not misleading, and that in the case of the
prospectus, it will not contain any untrue statement of a material fact or any
omission to state a material fact required to be stated therein or necessary to
make the statements therein, in the light of the circumstances under which they
were made, not misleading; or 

 

7

 

(v) that the Board has
made the good faith determination (A) that continued use by the selling
Investors of the Registration Statement for purposes of effecting offers or
sales of Registrable Shares pursuant thereto would require, under the
Securities Act, premature disclosure in the Registration Statement (or the
prospectus relating thereto) of material, nonpublic information concerning the
Company, its business or prospects or any proposed material transaction
involving the Company, (B) that such premature disclosure would be
materially adverse to the Company, its business or prospects or any such
proposed material transaction or would make the successful consummation by the
Company of any such material transaction significantly less likely and
(C) that it is therefore essential to suspend the use by the Investors of
such Registration Statement (and the prospectus relating thereto) for purposes
of effecting offers or sales of Registrable Shares pursuant thereto, then the
Company shall furnish to the selling Investors a certificate signed by the
Chairman of the Board of the Company setting forth one or more of the above
described circumstances, and the right of the selling Investors to use the
Registration Statement (and the prospectus relating thereto) shall be suspended
for a period (the “Suspension Period”) of not
more than ninety (90) days after delivery by the Company of the certificate
referred to above in this Section 11; provided
that  the Company shall be entitled to no
more than one such Suspension Period during the twelve (12) month period
commencing on the Initial Closing and during each subsequent twelve (12) month
period until the Mandatory Registration Termination Date (including any
extension thereto).  During the Suspension Period, (1) the Company
shall not register, offer or sell any of its securities other than pursuant to
a registration statement on Form S-8, and (2) none of the Investors
shall offer or sell any Registrable Shares pursuant to or in reliance upon the
Registration Statement (or the prospectus relating thereto).  For the first thirty (30) days after
commencement of a Suspension Period, each of the Investors shall keep the fact
of the above-described certificate and its contents confidential.  The
Company shall use reasonable best efforts to terminate any Suspension Period as
promptly as practicable.

 

12.           TRANSFER OF REGISTRATION RIGHTS.  None of
the rights of any Investor under this Agreement shall be transferred or
assigned to any person unless (i) such person is a Qualifying Holder (as
defined below), and (ii) such person agrees to become a party to, and
bound by, all of the terms and conditions of, this Agreement by duly executing
and delivering to the Company an Instrument of Adherence in the form attached
as EXHIBIT B  hereto.  For purposes of this
Section 12, the term “Qualifying Holder”
shall mean, with respect to any Investor, (i) any partner or member or
retired member or partner thereof, (ii) any corporation, partnership or
limited liability company controlling, controlled by, or under common control
with, such Investor or any partner or member thereof, or (iii) any other
transferee who is at the time of such transfer an “accredited investor,” as
defined in Rule 501(a) of Regulation D under the Securities Act
and receives at least 20% of those Registrable Shares held by such
Investor.  None of the rights of any
Investor under this Agreement shall be transferred or assigned to any person
(including, without limitation, a Qualifying Holder) that acquires Registrable
Shares in the event that and to the extent that such person is eligible to
resell such Registrable Shares pursuant to Rule 144 without
restrictions.  After any transfer in accordance with this Section 12,
the rights and obligations of an Investor as to any transferred Registrable
Shares shall be the rights and obligations of the Investor Permitted Transferee
holding such Registrable Shares.

 

13.           ENTIRE AGREEMENT.  This
Agreement, the Warrants and the Purchase Agreement constitute and contain the
entire agreement and understanding of the parties with respect to the subject
matter hereof, and supersede any and all prior negotiations, correspondence,
agreements or understandings with respect to the subject matter hereof.

 

14.           MISCELLANEOUS.

 

(a)           This Agreement may not be
amended, modified or terminated, and no rights or provisions may be waived,
except with the written consent of the Majority Holders and the Company;  provided,
however, that this Agreement may not be amended, modified or terminated,
and no

 

8

 

rights or provisions may be
waived, in any way that adversely affects the rights and/or obligations of any
Investor under this Agreement in a manner materially different from the manner
in which it affects the rights and/or obligations of the other Investors
without the written consent of such adversely affected Investor. The Company
shall give prompt written notice of any amendment, modification, termination or
waiver hereof to any party hereto that did not consent in writing to such
amendment, modification, termination or waiver. Any amendment, modification,
termination or waiver effected in accordance with this
Section 14(a) shall be binding on all parties hereto, even if they do
not execute such consent.

 

(b)           This Agreement shall be
governed by and construed and enforced in accordance with the laws of the State
of California and without regard to any conflicts of laws concepts which would
apply the substantive law of some other jurisdiction, and shall be binding upon
and inure to the benefit of the parties hereto and their respective heirs,
personal representatives, successors or assigns provided  that the terms and conditions of
Section 12 hereof are satisfied.  This Agreement shall also be
binding upon and inure to the benefit of any transferee of any of the
Registrable Shares provided that
the terms and conditions of Section 12 hereof are satisfied. 
Notwithstanding anything in this Agreement to the contrary, if at any time any
Investor shall cease to own any Registrable Shares, all of such Investor’s
rights under this Agreement shall immediately terminate.

 

(c)           Any notices, reports or
other correspondence (hereinafter collectively referred to as “correspondence”) required or
permitted to be given hereunder shall be in writing, addressed as set forth
below and shall be deemed effectively given: (a) upon personal delivery to
the party to be notified, (b) when sent by confirmed electronic mail or
facsimile if sent during normal business hours of the recipient, if not, then
on the next business day, (c) three business (3) days after having
been sent by registered or certified mail, return receipt requested, postage
prepaid, or (d) one (1) day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written
verification of receipt, in each case costs prepaid.

 

(i)            All correspondence to the
Company shall be addressed as follows:

 

	
  ARYx
  Therapeutics, Inc.

  
	
  6300
  Dumbarton Circle

  
	
  Fremont,
  CA 94555

  
	
  Attention:

  	
  Paul Goddard, Ph.D.

  
	
   

  	
  Chairman of the Board and

  
	
   

  	
  Chief Executive Officer

  
	
  Facsimile:

  	
  510-585-2202

  

 

with
a copy to (which shall not constitute
notice):

 

	
  Cooley LLP

  
	
  3175 Hanover Street

  
	
  Palo Alto, CA 94304

  
	
  Attention:

  	
  Jim F. Fulton, Jr., Esq.

  
	
  Facsimile:

  	
  650-849-7400

  

 

(ii)           All correspondence to any
Investor shall be sent to such Investor at the address set forth in EXHIBIT A.

 

(iii)          Any entity may change the
address to which correspondence to it is to be addressed by ten (10) days
advance written notification as provided for herein.

 

9

 

(d)           The parties acknowledge and
agree that in the event of any breach of this Agreement, remedies at law may be
inadequate, and each of the parties hereto shall be entitled to seek specific
performance of the obligations of the other parties hereto and such appropriate
injunctive relief as may be granted by a court of competent jurisdiction.

 

(e)           Should any part or provision
of this Agreement be held unenforceable or in conflict with the applicable laws
or regulations of any jurisdiction, the invalid or unenforceable part or
provisions shall be replaced with a provision which accomplishes, to the extent
possible, the original business purpose of such part or provision in a valid
and enforceable manner, and the remainder of this Agreement shall remain
binding upon the parties hereto.

 

(f)            This Agreement may be
executed in a number of counterparts, any of which together shall for all
purposes constitute one Agreement, binding on all the parties hereto
notwithstanding that all such parties have not signed the same counterpart. A
facsimile, telecopy or other reproduction of this Agreement may be executed by
one or more parties hereto and delivered by such party by facsimile or any
similar electronic transmission device pursuant to which the signature of or on
behalf of such party can be seen. Such execution and delivery shall be
considered valid, binding and effective for all purposes.  At the request
of any party hereto, all parties hereto agree to execute and deliver an
original of this Agreement as well as any facsimile, telecopy or other
reproduction hereof.

 

[SIGNATURE
PAGE TO FOLLOW]

 

10

 

IN WITNESS
WHEREOF, the parties hereto have executed this REGISTRATION RIGHTS AGREEMENT as of the date and year first
above written.

 

	
   

  	
  ARYx
  THERAPEUTICS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Paul Goddard

  
	
   

  	
  Name:

  	
  Paul
  Goddard, Ph.D.

  
	
   

  	
  Title:

  	
  Chairman
  of the Board and

  
	
   

  	
   

  	
  Chief
  Executive Officer

  

 

SIGNATURE PAGE TO ARYx THERAPEUTICS, INC.

REGISTRATION
RIGHTS AGREEMENT

 

 

	
  INITIAL
  INVESTOR:

  	
  AYER CAPITAL PARTNERS MASTER FUND,
  L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  Ayer
  Capital Partners, LLC, its general partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Jay Venkatesan

  
	
   

  	
   

  	
   

  
	
   

  	
  Print
  Name:

  	
  Jay
  Venkatesan

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:
  

  	
  Managing
  Member

  
	
   

  	
   

  	
   

  
	
   

  	
  Address:

  	
  Ayer
  Capital Management, L.P.

  
	
   

  	
   

  	
  Attn: Jay Venkatesan

  
	
   

  	
   

  	
  230 California Street,
  Suite 600

  
	
   

  	
   

  	
  San
  Francisco, CA 94123

  
	
   

  	
   

  	
  fax:
  (415) 651-9005

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  AYER CAPITAL PARTNERS KESTREL FUND,
  L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:
  

  	
  Ayer
  Kestrel Partners, LLC, its general partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Jay Venkatesan

  
	
   

  	
   

  	
   

  
	
   

  	
  Print
  Name:

  	
  Jay
  Venkatesan

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:
  

  	
  Managing
  Member

  
	
   

  	
   

  	
   

  
	
   

  	
  Address:

  	
  Ayer Capital Management,
  L.P.

  
	
   

  	
   

  	
  Attn: Jay Venkatesan

  
	
   

  	
   

  	
  230 California Street,
  Suite 600

  
	
   

  	
   

  	
  San
  Francisco, CA 94123

  
	
   

  	
   

  	
  fax:
  (415) 651-9005

  
				

 

SIGNATURE PAGE TO ARYx THERAPEUTICS, INC.

REGISTRATION RIGHTS AGREEMENT

 

 

	
  INITIAL
  INVESTOR:

  	
  MPM BIOVENTURES III, L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:  

  	
  MPM BioVentures III GP,
  L.P., its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
  MPM BioVentures III LLC,
  its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Nicholas Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Print
  Name:

  	
  Nicholas
  Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:
  

  	
  Series A
  Member

  
	
   

  	
   

  	
   

  
	
   

  	
  Address:

  	
  200 Clarendon Street, 54th Floor

  
	
   

  	
   

  	
  Boston,
  MA 02116

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  MPM BIOVENTURES III-QP, L.P.

  
	
   

  	
   

  
	
   

  	
  By:  

  	
  MPM BioVentures III GP,
  L.P., its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  MPM BioVentures III LLC,
  its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:
  

  	
  /s/
  Nicholas Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Print
  Name:

  	
  Nicholas
  Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:
  

  	
  Series A
  Member

  
	
   

  	
   

  	
   

  
	
   

  	
  Address:

  	
  200 Clarendon Street, 54th Floor

  
	
   

  	
   

  	
  Boston, MA 02116

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS
  KG

  
	
   

  	
   

  
	
   

  	
  By:  

  	
  MPM BioVentures III GP,
  L.P., in its capacity as Managing Limited Partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
  MPM BioVentures III LLC,
  its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:
  

  	
  /s/
  Nicholas Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Print
  Name:

  	
  Nicholas
  Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:
  

  	
  Series A
  Member

  
	
   

  	
   

  	
   

  
	
   

  	
  Address:

  	
  200 Clarendon Street, 54th Floor

  
	
   

  	
   

  	
  Boston,
  MA 02116

  
				

 

SIGNATURE PAGE TO ARYx THERAPEUTICS, INC.

REGISTRATION RIGHTS AGREEMENT

 

 

	
  INITIAL INVESTOR:

  	
  MPM BIOVENTURES III PARALLEL FUND, L.P.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:  

  	
  MPM BioVentures III GP,
  L.P., its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
  By: 

  	
  MPM BioVentures III LLC,
  its General Partner

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:
  

  	
  /s/
  Nicholas Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Print
  Name:

  	
  Nicholas
  Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:
  

  	
  Series A
  Member

  
	
   

  	
   

  	
   

  
	
   

  	
  Address:

  	
  200 Clarendon Street, 54th Floor

  
	
   

  	
   

  	
  Boston,
  MA 02116

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:
  

  	
  /s/
  Nicholas Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Print
  Name: 

  	
  Nicholas
  Simon III

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:
  

  	
  Manager

  
	
   

  	
   

  	
   

  
	
   

  	
  Address:

  	
  200 Clarendon Street, 54th Floor

  
	
   

  	
   

  	
  Boston,
  MA 02116

  
				

 

SIGNATURE PAGE TO ARYx THERAPEUTICS, INC.

REGISTRATION RIGHTS AGREEMENT

 

 

EXHIBIT A

 

Investor Name and Address

 

Ayer
Capital Partners Master Fund, L.P.

 

Ayer
Capital Partners Kestrel Fund, L.P.

 

Attn: Jay
Venkatesan

230 California Street,
Suite 600

San Francisco, CA
94111

 

MPM
BioVentures III, L.P.

 

MPM
BioVentures III-QP, L.P.

 

MPM
BioVentures III GmbH & Co. Beteiligungs KG

 

MPM
BioVentures III Parallel Fund, L.P.

 

MPM Asset
Management Investors 2002 BVIII LLC

 

230
Clarendon Street, 54th Floor

Boston,
MA 02116

 

A-1

 

EXHIBIT B

 

Instrument of Adherence

 

Reference is hereby made to that certain Registration Rights Agreement,
dated as of August 13, 2010, among ARYx Therapeutics, Inc., a
Delaware corporation (the “Company”),
the Initial Investors and the Investor Permitted Transferees, as amended and in
effect from time to time (the “Registration Rights
Agreement”). Capitalized terms used herein without definition
shall have the respective meanings ascribed thereto in the Registration Rights
Agreement.

 

The
undersigned, in order to become the owner or holder of
[                      ]
shares of common stock, par value $0.001 per share (the “Common
Stock”), of the Company, hereby agrees that, from and after the
date hereof, the undersigned has become a party to the Registration Rights
Agreement in the capacity of an Investor Permitted Transferee, and is entitled
to all of the benefits under, and is subject to all of the obligations, restrictions
and limitations set forth in, the Registration Rights Agreement that are
applicable to Investor Permitted Transferees. 
This Instrument of Adherence shall take effect and shall become a part
of the Registration Rights Agreement immediately upon execution.

 

Executed
as of the date set forth below under the laws of the State of California.

 

 

	
   

  	
   

  	
  Signature:

  	
   

  
	
   

  	
   

  	
   

  	
  Name:

  
	
   

  	
   

  	
   

  	
  Title:

  
	
   

  	
   

  	
   

  
	
  Accepted:

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  [                                               ]

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
   

  	
   

  
	
   

  	
  Title:

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
  Date:

  	
                    ,
  20

  	
   

  	
   

  

 

B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]